Design and synthesis of conformationally constrained ligands for Grb2 SH2 binding and thermodynamic evaluation and the development of a diversity oriented synthesis of 2-arylpiperidines by Goodnough, Alex Michael
 
 
 
 
 
 
 
 
 
Copyright 
by 
Alex Michael Goodnough 
2016 
 
 
The Thesis Committee for Alex Michael Goodnough 
Certifies that this is the approved version of the following thesis: 
 
 
Design and Synthesis of Conformationally Constrained Ligands for 
Grb2 SH2 Binding and Thermodynamic Evaluation and The 
Development of a Diversity Oriented Synthesis of 2-Arylpiperidines 
 
 
 
 
 
 
 
 
APPROVED BY 
SUPERVISING COMMITTEE: 
 
 
 
Stephen F. Martin, Supervisor 
Eric V. Anslyn 
 
  
Supervisor: 
Design and Synthesis of Conformationally Constrained Ligands for 
Grb2 SH2 Binding and Thermodynamic Evaluation and The 
Development of a Diversity Oriented Synthesis of 2-Arylpiperidines 
 
 
 
 
by 
Alex Michael Goodnough, B. S. 
 
 
Thesis 
Presented to the Faculty of the Graduate School of  
The University of Texas at Austin 
in Partial Fulfillment  
of the Requirements 
for the Degree of  
 
Master of Arts 
 
 
The University of Texas at Austin 
December, 2016 
 Dedication 
 
To my older brother Phil, whose incessant know-it-all-ism drove me to achieve at 
the highest level, and prepared me for the academic world. 
 
 v 
Acknowledgements 
 
I’d like to thank Professor Stephen F. Martin, for accepting me into his lab and 
always encouraging me to perform my best in lab, and in the classroom. I’d like to thank 
every member of lab 2, past and present, for always keeping our work environment fun 
and exciting. I’d like to thanks my current and former lab mates David Cramer, Caleb 
Hethcox, Daniel Klosowski, Lance Lepovits, And Zachary White, for teaching me how to 
act like I knew what I was doing. I’d also like to especially thank Ian Riddington, Steve 
Sorey, and Angela Spangenberg, for their help in characterizing compounds. 
I must also thank my mother Lorraine, my father Bruce, and all my family 
members who encouraged and supported me along the way. Lastly, I thank Emma 
Dietrich, for standing by my side through the highs and lows of the past two years.  
 
 vi 
Abstract 
 
Design and Synthesis of Conformationally Constrained Ligands for 
Grb2 SH2 Binding and Thermodynamic Evaluation and The 
Development of a Diversity Oriented Synthesis of 2-Arylpiperidines 
 
 
Alex Michael Goodnough, M. A. 
The University of Texas at Austin, 2016 
 
Supervisor:  Stephen F. Martin 
 
The ways in which torsional strain in the bound form of a ligand affects the 
energetics of protein binding are poorly understood. In order to study this feature of 
protein-ligand interactions, a conformationally constrained ligand for Grb2 SH2 
containing a 1,1,2 trisubstituted cyclopropane was designed, and the synthesis of this 
ligand attempted.  
Additionally, a novel iminium ion formation/cyclization cascade was applied to 
the synthesis of a library of 2-arylpiperidines with varying aryl group substitution, and 
nitrogen atom functionalization. This strategy should allow further access to chemical 
space already identified as containing potential therapeutics and tool compounds for 
biological interrogation. 
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CHAPTER 1: CONFORMATIONALLY CONSTRAINED LIGANDS 
FOR GRB2-SH2 
1.1 Introduction 
A major challenge in the process of drug discovery and development, as well as 
the study of molecular recognition in biological systems, is predicting and understanding 
how changes to the structural features of drug leads and small molecules will affect their 
relative binding affinities.1-3 Addressing this challenge is non-trivial because the free 
energy of binding (ΔG°) for an interaction frequently fails to correlate with enthalpy 
(ΔH°) and/or entropy (-TΔS°) of binding, requiring in depth thermodynamic analysis in 
order to determine how changes in binding affinity (Ka) arise.4 Unfortunately, progress in 
molecular recognition efforts have been hampered by the scarcity of published 
experiments where ΔH° and –TΔS° are determined for a series of incrementally modified 
ligands.  
Optimization of protein ligand interactions generally utilizes strategies that are 
believed to have predictable effects on both ∆H° and ∆S° of binding. For instance, 
maximization of non-covalent interactions between the ligand and the protein should 
increase binding enthalpy. Optimizing such interactions in practice, however, is very 
challenging because desolvating polar functionalities is enthalpically unfavorable. This 
penalty often outweighs the enthalpic benefit gained from increasing the strength of non-
covalent interactions, leading to a precarious balancing act.5 Polar interactions are also 
highly angle and distance dependent, further complicating the process of optimizing these 
interactions.6 These challenges make clear that a qualitative understanding of the non-
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covalent interactions at play in biomolecular recognition is not sufficient for prediction of 
the effects changes in structure will have on binding enthalpy. 
Optimization of binding entropy is another approach to increasing binding affinity. Such 
strategies are frequently based on a qualitative understanding of the role entropy plays in 
protein-ligand interactions. One such approach involves the incorporation of 
conformational constraints into a ligand.7,8 These constraints are typically installed with 
the intention of reducing the conformational entropy of the unbound ligand (Figure 1.1), 
thereby making ∆S° of binding more favorable.9 However, conformational constraints 
frequently result in unanticipated, compensatory decreases in the ∆H° of binding. 
Additionally, there are examples of conformational constraints increasing ∆G° while 
having a negative impact on ∆S° of binding, illuminating deficiencies in our 
understanding of protein ligand interactions.10 
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Figure 1.1: Comparison of Ka for flexible (top) and constrained (bottom) ligands. Ka is 
generally assumed to increase due to more favorable ∆S° of binding. 
 
 The favorability of binding entropy is also frequently enhanced via increasing the 
hydrophobic surface area buried upon binding. This strategy relies on our understanding 
of how solvent behaves when it hydrates the surface of a protein. When a protein is 
dissolved in water, the system is essentially made up of three parts. These are the bulk 
solvent, the solvent hydrating the surface of the protein, and the protein itself. The bulk 
solvent is believed to tumble freely through the system, which is entropically favorable. 
This high translational and rotational entropy is thought to be enthalpically unfavorable, 
as it limits the hydrogen bonding capabilities of bulk solvent due to the high distance and 
angle dependency of these interactions. The water molecules involved in hydrating the 
protein are thought to be far less mobile than the bulk solvent, in order to maintain the 
most favorable contacts possible with the proteins surface. While maintaining the ideal 
+
Ka
Protein Protein-Ligand Complex
+
Ka
Protein Protein-Constrained Ligand Complex
Ligand
Constrained Ligand
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energetic contacts possible with the protein is enthalpically favorable, the “frozen” nature 
of these water molecules is thought to be entropically unfavorable (Figure 1.2) 
Figure 1.2: A Dissolved Protein with Hydrating Water Molecules (Blue) and Bulk 
Solvent Molecules (Red) 
 
 Now consider a binding event taking place between a protein and a small, 
hydrophobic molecule in aqueous solution (Figure 1.3). The protein and small molecule 
are initially both hydrated by “frozen” water molecules, which interact with the bulk 
solvent to keep each binding partner in solution. When these two molecules make contact 
in a binding event, hydrating water molecules are released into the bulk solvent to make 
room for new protein/ligand contact points, essentially “burying” the hydrophobic 
surfaces that were previously hydrated. Because bulk solvent molecules have greater 
entropy than molecules involved in hydration, this process is believed to be entropically 
favorable. Thus, by increasing the amount of hydrophobic surface area on a ligand, we 
can minimize entropic penalties paid upon binding to the protein.  
Hydrated Protein
Bulk Solvent
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Figure 1.3: A Protein-Ligand Binding Event in Aqueous Solution 
 
 
 While taking advantage of the hydrophobic effect for enhancing binding affinities 
seems simple, burying hydrophobic surface area is far from an ideal strategy for 
increasing binding affinities. First, there are strict limitations on the amount of 
hydrophobic surface area that can be added to a ligand before it’s solubility in aqueous 
solution becomes too low to be useful for biological interrogation. Additionally, because 
desolvating hydrophobic groups is so energetically favorable, excessive greasiness can 
increase the promiscuity of ligands. Lastly, the behavior of water molecules involved in 
hydrophobic hydration changes depending on the contour of the surface being hydrated. 
For instance, when a small hydrophobic molecule is dissolved in water, the hydrating 
molecules form a “clathrate-like” structure around the solute. This arrangement allows 
the water molecules to make 100% of their potential hydrogen bonding contacts. When 
larger hydrophobic molecules are dissolved in water, such as a protein, the water 
molecules can satisfy a maximum of 75% of their potential hydrogen bonding contacts.11 
While this disruption of hydrogen bonding is not enthalpically favorable, there are 
entropic benefits that come from a slight increase in the rotational freedom of the 
hydrating water molecules (Figure 1.4).12 
+ Ka
Hydrated Protein Hydrated Protein-Ligand ComplexHydrated Ligand
+
Displaced Water
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Figure 1.4: Comparison of Hydration of a Small Hydrophobic Solute and a Large 
Hydrophobic Solute (Represented Here as a Flat Surface) 
 
 
The common downfall of the above strategies is the inability to consistently 
overcome enthalpy-entropy compensation (H/S compensation), which refers to the 
tendency for favorable changes in ∆H° to be counteracted by unfavorable changes in ∆S°, 
or vice versa. H/S compensation frequently plagues efforts to increase the Ka of a ligand 
in biomolecular recognition experiments.13 The phenomenon is observed so frequently 
that it has been proposed to be a general feature of weak intermolecular interactions in 
aqueous media; however, experiments and statistical analyses have shown this not to be 
true.14,15 While H/S compensation may not be a phenomenon intrinsically associated with 
biomolecular recognition, its presence in many such studies cannot be denied.16-18  
 1.1.1  1,2,3-TRISUBSTITUTED CYCLOPROPANES AS CONFORMATIONAL CONSTRAINTS 
 
In 2002 the Martin group set out to establish whether 1,2,3-trisubstituted 
cyclopropane rings could serve as useful constraints for ligand preorganization.19 The 
study compared a series of flexible ligands for the Src SH2 domain 1.1 and 1.2, to 
constrained 1,2,3-trisubstituted cyclopropane analogs 1.3 and 1.4. The thermodynamics 
of binding each ligand to Src SH2 were compared using isothermal titration calorimetry 
(ITC). 
H
O
H
H
O
H
H
O
HH
O
H
enthalpically favorable
O
H
H
H
O
H
H
O
H
entropically favorable
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Isothermal titration calorimetry is a method by which a solution of one binding partner is 
titrated into a solution of another binding partner in small increments. The energy 
required to maintain constant temperature is measured and integrated against 
stoichiometry. The energy required to maintain constant temperature gives ∆H°, and the 
slope of the line at the equivalence point gives the Ka. Knowing these two parameters 
allows us to calculate the ∆S° and ∆G° of binding as well.  
Table 1.1: Constrained (left) and flexible (right) ligands studied by the Martin group in 
2002. 
 
Compounds Ka ∆G°obs  
(kcal mol-1) 
∆H°obs 
 (kcal mol-1) 
∆S°obs  
(cal mol-1) 
1.1 1.0 (±0.1) × 107 -9.55 ± 0.07 -5.91 ± 0.04 17 ± 1 
1.3 1.7 (±0.6) × 107 -9.8 ± 0.2 -7.33 ± 0.03 8.3 ± 0.5 
1.2 6.3 (±0.6) × 106 -9.26 ± 0.06 -5.01 ± 0.05 14.3 ± 0.4 
1.4 1.4 (±0.1) × 107 -9.72 ± 0.06 -6.92 ± 0.09 9.4 ± 0.2 
 
As is seen in Table 1.1, constrained ligands 1.1 and 1.2 enjoyed more favorable 
∆S° of binding compared to flexible counterparts 1.3 and 1.4, respectively. However, this 
favorable ∆∆S° was counteracted by an unfavorable ∆∆H° of binding for each 
N
R
Me
O
H
H
H2O3PO
O
H
N
N
H
O
H
N
O
OH
O
CO2H
CO2H
1.1: R = H
1.2: R = Me
Me
N
H
N
N
H
O
O
O
O
H
N
OH
O
R
H2O3PO
CO2H
CO2H
1.3: R = H
1.4: R = Me
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constrained ligand. This apparent H/S compensation resulted in almost no ∆∆G° between 
the constrained and flexible ligands.  
 In order to gain insight as to what caused this unfavorable ∆∆H° the complex of 
Src SH2 with 1.1 (Src SH2–1.1) was studied with x-ray crystallography. Comparison of 
the crystal structure of Src SH2–1.1 complex with the Src SH2–1.3 complex revealed 
very few differences in the bound conformation of 1.1 and 1.3 (Figure 1.5).  
Figure 1.5: Overlay of 1.1 (red and salmon) with the 1.3 (black and white) in the bound 
state. All conformations present in the asymmetric unit of each crystal 
structure are shown. 
 
 
Although no significant differences were found in how ligand 1.1 and 1.3 bound 
to Src SH2, a significant difference in the structure of the SH2 domain was found in the 
two crystal structures. The pTyr residue of each ligand interacts with Arg residue αA2 in 
the binding pocket of Src SH2 (Figure 1.6). 
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Figure 1.6: Interactions of the pTyr (PTR) residue of 1.1 with Arg αA2. The 
conformation of Arg αA2 in the complex of Src SH2 with the native ligand 
is overlayed. 
 
The conformation of Arg αA2 is significantly different in the complex of Src SH2–1 and 
Src SH2–11-mer. The change in conformation of Arg αA2 results in a change in the 
hydrogen bonding network of the complex, breaking a hydrogen bond between Arg αA2 
and the pTyr residue while creating a new hydrogen bond with a water molecule. 
Additionally, Arg αA2 is moved 0.5 Å further away from the aromatic face of the 
constrained pTyr residue, potentially disrupting a cation-π interaction between the 
guanidine of Arg αA2 and the aromatic ring of pTyr. The introduction of the 
cyclopropane ring appears to have given rise to torsional strain in the bound form of 
ligand 1.1. The thermodynamic consequences of small internal strains in the bound state 
of a ligand, however, difficult to assess.  
 In order to determine if structural differences in the SH2 domain of the Src SH2–
1.1 and Src SH2–1.3 complexes were the source of the H/S compensation observed with 
ligands 1.1 and 1.3, Ward et al. carried out NMR experiments and molecular dynamics 
(MD) simulations.21 The NMR experiments revealed downfield chemical shift 
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perturbations (CSPs), which arise from increased deshielding of a proton and reflect 
stronger hydrogen-bonding interactions, were observed for several residues in the 
complexes of 1.1 and 1.2 with Src SH2.  These CSPs took place most frequently at the 
pTyr-binding pocket of the SH2 domain. Downfield CSPs are the result of increased 
deshielding of protons,22 which indicate an increase in hydrogen bonding interactions. 
Downfield CSPs were present in both Src SH2–1.1 and Src SH2–1.2 complexes. While 
chemical shift perturbations reflect changes in hydrogen bonding that occur upon 
complex formation, chemical shift differences (CSDs) represent differences in the 
chemical shifts of different complexes. The CSDs linearly correlated with the ∆H° of 
binding for pYEEI, ligand 1.1, and ligand 1.2 to Src SH2. The most enthalpically stable 
complex, Src SH2–pYEEI, had the largest CSDs, while the least enthalpically favorable 
complex, Src SH2–1.1, had the smallest CSDs. This correlation suggests that hydrogen 
bonding interactions at the pTyr-binding site have been compromised as a result of the 
constraint.  
 Binding interactions between Src SH2 and pTyr comprise more the 50% of ∆G° 
for binding ligands to Src SH2, classifying this region as a binding “hotspot.”23 It was 
determined that disturbances in the interaction of the pTyr residue with Src SH2 brought 
about by the installation of the cyclopropane ring are likely the source of H/S 
compensation. It is noteworthy that the NMR studies revealed many differences in 
hydrogen bonding interactions that were not visible in the X-ray crystal structures of any 
complex with Src SH2. This result is concerning because such detailed information is 
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rarely available at the outset of rational ligand design campaigns, making the 
consequences of ligand modifications difficult to predict. 
In order to further study the use of 1,2,3-trisubstituted cyclopropanes as 
conformational constraints in biomolecular recognition studies, flexible and constrained 
ligands of the general sequence Ac-pYXN-NH2 (X = V, I, L, K, Q, or E) were prepared, 
and the thermodynamics of binding these ligands to Grb2 SH2 were obtained via ITC 
(Table 1.2).24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 12 
Table 1.2: Thermodynamic binding data for constrained and flexible analogs of Ac-
pYXN-NH2. 
 
Ligand Ka 
(M-1) 
∆G° 
(kcal mol-1) 
∆H° 
(kcal mol-1) 
∆S° 
(cal mol-1) 
1.5 
1.11 
(4.5 ± 0.12) × 105 
(2.8 ± 0.10) × 106 
-7.7 ± 0.02 
-8.8 ± 0.02 
-5.4 ± 0.14 
-7.9 ± 0.29 
7.9 ± 0.22 
3.0 ± 0.30 
1.6 
1.12 
(4.0 ± 0.15) × 105 
(2.1 ± 0.08) × 106 
-7.7 ± 0.02 
-8.6 ± 0.02 
-5.5 ± 0.20 
-8.3 ± 0.30 
7.4 ± 0.30 
1.3 ± 0.30 
1.7 
1.13 
(1.7 ± 0.06) × 105 
(7.1 ± 0.27) × 105 
-7.1 ± 0.02 
-8.0 ± 0.02 
-4.6 ± 0.17 
-6.0 ± 0.22 
8.6 ± 0.30 
6.6 ± 0.30 
1.8 
1.14 
(5.6 ± 0.15) × 105 
(1.2 ± 0.06) × 106 
-7.8 ± 0.02 
-8.3 ± 0.01 
-8.7 ± 0.23 
-9.8 ± 0.20 
-2.8 ± 0.22 
-5.2 ± 0.18 
1.9 
1.15 
(3.0 ± 0.08) × 105 
(3.6 ± 0.10) × 105 
-7.5 ± 0.02 
-7.6 ± 0.02 
-8.8 ± 0.23 
-10.3 ± 0.27 
-4.3 ± 0.22 
-9.0 ± 0.22 
1.10 
1.16 
(9.8 ± 0.23) × 104 
(5.5 ± 0.15) × 105 
-6.8 ± 0.02 
-7.8 ± 0.02 
-7.7 ± 0.20 
-9.2 ± 0.24 
-3.0 ± 0.21 
-4.6 ± 0.22 
 
It was known at the outset of this study that the pTyr group of pYXN ligands 
bound to Grb2 SH2 in a fashion conformationally similar to Src SH2-pYEEI complexes. 
Surprisingly, in spite of this similarity, the ∆∆G°, ∆∆H°, and ∆∆S° for constraining 
pYXN ligands were very different from the results obtained with Src. Initially apparent is 
N
H
Me
O
Xaa-Asn-NH2
O
H2O3PO
N
H
Me
O
Xaa-Asn-NH2
O
H2O3PO
1.5: Xaa = Val
1.6: Xaa = Ile
1.7: Xaa = Leu
1.8: Xaa = Gln
1.9: Xaa = Glu
1.10: Xaa = Lys
1.11: Xaa = Val
1.12: Xaa = Ile
1.13: Xaa = Leu
1.14: Xaa = Gln
1.15: Xaa = Glu
1.16: Xaa = Lys
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the increase in binding affinity gained from constraining every pYXN ligand, which is 
reflected in the negative ∆∆G° values for each flexible/constrained pair. Even more 
surprising is the observation that in each case, negative ∆∆G° values result from a more 
negative ∆∆H° that overcomes less favorable ∆∆S° values. These results were the first to 
demonstrate the increased Kas resulting from conformational constraints are not 
necessarily the result of more favorable binding entropy. 
Structural studies comparing flexible and constrained pYXN ligands showed that 
the ligands bound in a similar manner to one another. The constrained ligand of a given 
pair made more direct contacts with the domain, so there was a qualitative correlation 
between the total number of direct protein-ligand contacts and the relative ∆H° and ∆G° 
for each ligand pair. Conversely, the more flexible ligand of a pair made more single 
water-mediated contacts with the domain. Additionally, variations in binding enthalpies 
and entropies for the flexible and constrained ligands did not appear to arise from 
differences in either proton exchange or desolvation phenomena. There were no 
significant differences in the van der Waals contacts for a given flexible/constrained 
ligand pair. An analysis of crystallographic b-factors suggested that thermal motions in 
complexes of the constrained ligands were generally greater than those in the 
corresponding complexes of their flexible controls. If these motions in the solid state 
actually reflect more disorder, and hence more favorable configurational entropies, in the 
complexes of constrained ligands, one might anticipate that the binding entropies for their 
formation would be greater than those for their flexible counterparts; however, this 
prediction is inconsistent with our results.  
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 Since structural analysis of the complexes of ligands 1.5-1.16 with Grb2 SH2 
failed to explain the unexpected results of the experiment, focus was turned towards the 
solution state conformational dynamics of the unbound ligands.25 Computations 
analyzing the solution state conformation of flexible ligand 1.5 and constrained ligand 
1.11 actually predicted that flexible ligand 1.11 had lower entropy than its constrained 
counterpart. This is due to the dominant solution state conformation (35 mol%) of ligand 
1.11 being macrocyclic in nature. As seen in Figure 1.7, the phosphate group of ligand 
1.11 makes an intramolecular hydrogen bond with the amide moiety at the C-terminus of 
the molecule.  
Figure 1.7: 35 mol% of Ligand 1.11 Exists in the Macrocyclic Conformation Below 
 
The cyclopropane in constrained ligand 1.5 prevents this interaction from 
occurring, thus increasing the solution state entropy of ligand 1.5 relative to its flexible 
counterpart. Thus, we have shown that lowering the entropy of a ligand in any way that 
allows it to adopt its bound conformation can lead to a more favorable entropy of 
binding. 
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1.1.2  USING CONFORMATIONAL CONSTRAINTS TO EVALUATE THE EFFECTS OF 
INTERNAL STRAIN IN THE BOUND FORM OF A LIGAND 
 
 In 2013, the Martin group studied the effects increasing the length of an alkyl 
chain at the pY+1 residue of Ac-pYXN-NH2 had on binding with Grb2 SH2.17 It was 
already known that ∆G° of binding linearly correlated with cycloalkane size at the pY+1 
region due to increasingly favorable ∆H° of binding.17,26 Interestingly, no such trend was 
observed with the linear alkyl chain containing ligands 1.22-1.25 (Table 1.3). 
Table 1.3: Thermodynamic Data for complex formation with Grb2 SH2. 
 
Ligand Ka ( × 105 M-1) 
∆G° 
(kcal mol-1) 
∆H° 
(kcal mol-1) 
-T∆S° 
(kcal mol-1) 
1.17 
1.22 
1.6 ± 0.1 
8.6 ± 0.2 
-7.1 ± 0.1 
-8.1 ± 0.1 
-3.3 ± 0.3 
-6.8 ± 0.5 
-3.8 ± 0.1 
-1.3 ± 0.1 
1.18 
1.23 
4.3 ± 0.4 
7.6 ± 1.0 
-7.7 ± 0.1 
-8.0 ± 0.1 
-5.4 ± 0.3 
-6.7 ± 0.5 
-2.3 ± 0.2 
-1.3 ± 0.3 
1.19 
1.24 
16.1 ± 1.1 
8.4 ± 0.6 
-8.5 ± 0.1 
-8.1 ± 0.1 
-6.3 ± 0.4 
-7.3 ± 0.3 
-2.2 ± 0.2 
-0.8 ± 0.2 
1.20 
1.25 
69.6 ± 12.0 
7.8 ± 0.6 
-9.3 ± 0.1 
-8.0 ± 0.1 
-8.5 ± 0.4 
-7.2 ± 0.3 
-0.8 ± 0.4 
-0.8 ± 0.2 
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Unlike 1.17-1.20, the addition of methylene groups in ligands 1.22-1.25 does not 
correlate with any thermodynamic parameter. Structural analysis of Grb2 SH2 complexes 
with compounds 1.22 through 1.25 revealed a gauche conformation along the Cß-Cγ bond 
of the alkyl side chain in the bound form of ligands 1.23-1.25 (Figure 1.8). Presumably, 
this energetically unfavorable conformation present in the bound form of the ligand is 
having undesirable effects on the ∆∆G° of binding. 
Figure 1.8: Structural Data for Grb2 SH2 complexes with 1.22-1.25 
 
This observation presents a unique opportunity to test if relieving torsional strain 
in the bound form of a ligand will enhance binding affinity. This is an important question 
because ligands rarely bind to proteins in their lowest energy conformation.27 Towards 
testing the effects of this torsional strain, ligand 1.26 was prepared (Figure 1.9a). This 
ligand contains a (Z)-propenyl side chain that was expected to remove torsional strain in 
the bound state while also removing a degree of rotational freedom prior to binding. 
Unfortunately, 1.26 bound with a thermodynamic signature that was identical to 1.23 
within experimental error. Structural analysis of the Grb2 SH2–1.26 complex revealed 
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that the side chain of 1.26 made fewer van der Waals (vdW) contacts to the protein than 
1.23 (Figure 1.9b). This suggests the (Z)-propenyl side chain weakened the dispersive 
interactions between the ligand and Grb2 SH2. 
Figure 1.9: (a) Constrained ligand 1.26 and (b) overlay of 1.26 (dark grey) and 1.23 (light 
grey) bound to the Grb2 SH2 domain. 
 
 As the Z-alkene apparently had not been an effective mimic of the free n-propyl 
side chain, it was decided that using a more sophisticated preorganizational constraint 
would be necessary. We therefore set out to find functionalities that would stabilize the 
gauche conformation upon binding without decreasing the number of vdW contacts in the 
complex. 
A unique solution to this quandary was found in ethylcyclopropane, which has 
been experimentally determined to exist in the gauche conformation under standard 
conditions (Figure 1.10a).28,29 Thus, installation of a cyclopropane into the alkyl chain at 
the α carbon of 1.23 to give 1.27 seems to be a viable method for lowering the enthalpic 
penalty of the gauche conformation in the bound form. Preparation of 1.27 can be 
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accomplished through incorporation of (-)-allo-coronamic acid (Aca) into the ligand 
(Figure 1.10b).  
Figure 1.10: (a) Newman projection of gauche and cis ethyl cyclopropane. (b) Proposed 
compound 1.27 and required (-)-allo-coronamic acid (1.28) 
 
1.2 Results and Discussion 
In 1991 Schöllkopf et al. reported the synthesis of (+)-allo-coronamic acid via 
chiral bislactim ether 1.33.30 While Schöllkopf’s auxiliary is commercially available, the 
desired enantiomer is quite expensive. Thus, the chiral auxiliary was synthesized from D-
valine (Scheme 1.1).31 Protection of D-valine followed by coupling with glycine methyl 
ester provided 1.31 in near quantitative yield. Heating the protected dipeptide in 1,2-
dichlorobenzene at 180 °C provided diketopiperazine 1.32 in 65% yield. Ethylation of 
1.32 furnished Schollkopf’s auxiliary (1.33) as a colorless liquid in 43% overall yield. 
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Scheme 1.1: Synthesis of Schöllkopf’s auxiliary (1.33). 
 
Alkylation of the glycine α-carbon of 1.33 with 1,4-dichlorobut-2-ene provided 
compound 1.34 in 75% yield. Upon addition of a second equivalent of n-BuLi, spirocycle 
1.35 was formed via intramolecular SN2’ displacement of chloride ion as a separable 
mixture of diastereomers (dr = 4:1, determined by 1H NMR). Many attempts were made 
to increase the dr of this cyclization reaction by changing the strength and steric bulk of 
the base, as well as using less coordinating solvents, but no increase in dr was observed. 
Hydrogenation of alkene 1.35 gave spirocycle 1.36, which upon hydrolysis provided 
amino ester 1.37 in an overall 7% yield from D-valine (Scheme 1.2) 
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Scheme 1.2: Synthetic route to (-)-(2S, 3R)-allo-coronamic ethyl ester (1.37), analogous 
to that of Schöllkopf et al.  
 
Amino ester 1.37 was then coupled to N-Boc-tyrosine to give protected dipeptide 
1.38 in 36% yield. LC/MS data for coupling of allo-coronamic ethyl ester with N-Boc-
tyrosine revealed a significant esterified byproduct (Equation 1.1).  
 
Saponification of ethyl ester 1.38 followed by coupling with asparagine amide gave 
tripeptide 1.40 in a combined 40% yield (Scheme 1.3) 
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Scheme 1.3: Initial attempt to synthesize ligand 1.27. 
 
 
This tripeptide was deprotected and acetylated in 50% yield to give Ac-Tyr-Aca-
Asn-NH2, but purification of this compound was challenging due to the low solubility of 
the tripeptide in organic solvents. While LC/MS analysis showed attempts to 
phosphorylate this material without purification produced the desired product, the 
procedure used was too low yielding to isolate any useful amount of material.32 (Equation 
1.2) 
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Optimizing the phosphorylation reaction at this late stage of the synthesis was not 
practical due to low yields in the peptide coupling and deprotection steps, so the approach 
to ligand 1.27 was modified. 
In order to stop the formation of esterified byproduct 1.42, phosphorylated 
tyrosine 1.43 was used as the initial coupling partner. Unfortunately, peptide coupling 
additives such as HOBt, HOAt, and Oxyma deprotected the phosphate moiety, leading to 
low yields of desired compound 1.45 (Equation 1.3). 
 
 
While it was possible to purify compound 44, the phosphate moiety proved to be 
unstable under basic conditions, making saponification of the ethyl ester low yielding, so 
a tert-butyl ether was used to protect the tyrosine sidechain in the initial coupling step.  
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While the tert-butyl ether allowed coupling of compound 37 with tyrosine in 50% yield, 
the saponification of ethyl ether 45 was still sluggish and low yielding (Equation 1.4). 
 
At this point it was decided the synthesis was not optimizable beyond the yields in 
Scheme 3, and the sequence would simply need to be performed on larger scale in order 
to access ligand 1.27. However, constraints on reagent availability made producing more 
cyclopropane prohibitively time consuming, and the project was put on hold. 
 
 1.3 Summary 
In summary, allo-coronamic acid was synthesized via a route reported by 
Schöllkopf et al.. Although the synthesis of allo-coronamic acid was initially thought to 
be the most complex portion of the synthesis of tripeptide 1.27, we found peptide 
couplings involving this α,α-disubstituted amino acid to be very low yielding, due in part 
to side reactions that were encouraged by the steric bulk at the α carbon of 1.37. 
Additionally, the liability of the dibenzyl phosphate group under peptide coupling 
conditions, combined with the large number of steps required to synthesize 1.27, made 
the synthesis more impractical than initially thought. Efforts to synthesize ligand 1.27 are 
still ongoing in the Martin lab.  
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CHAPTER 2: PREPARING A LIBRARY OF 2-ARYL PIPERIDINES 
VIA IMINIUM ION CASCADE REACTIONS 
2.1 Introduction 
 The preparation of large collections of organic compounds for biological 
screening campaigns has been a strategy on the forefront of drug discovery for decades. 
The strategy originally revolved around synthesizing a vast number of compounds by 
mixing and matching a few readily available building blocks in the hopes that one or 
more of the resulting compounds would display biological activity and lead the way to a 
new drug candidate. This technique did not lead to the number of new drug leads 
expected, likely because randomly generated libraries tend to lack the structural diversity 
necessary to efficiently probe chemical space.33  
 Newer approaches to library synthesis have revitalized this strategy, resulting in 
higher hit rates and more new lead compounds entering clinical trials per library 
created.34  One such approach is biology-oriented synthesis (BIOS).35 The primary factor 
separating BIOS from the synthesis of libraries comprised of random components is a 
focus on targeting libraries of compounds that are structurally similar to natural products. 
Because natural products are synthesized by binding to different enzymes in a series of 
chemical transformations, the subunits that make up natural products are frequently 
thought of as being biologically pre-validated. Thus, the BIOS strategy aims to guarantee 
that the regions of chemical space explored in a molecular library synthesis will at least 
be biologically relevant. 
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 Another approach that has gained traction is diversity-oriented synthesis (DOS).36 
The primary goal of DOS is simply to maximize the complexity of the molecules in a 
library. Increasing “complexity” is generally achieved by increasing the level of 
saturation and the number of stereogenic centers in a molecule. Thus, the key to DOS is 
to use simple, readily available building blocks, which offer opportunities to increase 
complexity with simple inter- and intramolecular reactions down the line. Ideally, 
researchers avoid occupying “dense” chemical space, which plagued traditional 
combinatorial chemistry efforts, by pursuing strategies that access multiple different 
scaffolds. 
In order to establish structural complexity in only a few steps, diversity oriented 
synthesis frequently employs multi-component reactions (MCRs).37-39 These reactions 
combine three or more components in a single step, which increases the level of 
complexity attainable in a single chemical transformation. By utilizing components with 
high functional group tolerance, we can create opportunities for further scaffold 
diversification after the MCR. Utilizing this strategy, MCRs allow quick access to 
collections of highly diverse scaffolds, each being derivatizable in unique ways.40-42 
Related to the MCR is the multi-component assembly process (MCAP). While an MCR 
constitutes a reaction with three or more reagents combined simultaneously to give one 
product, an MCAP uses three or more reagents in a specific sequence to form a new, 
higher complexity structure. 38,43,44 Together, the MCR and MCAP strategies represent the 
most efficient way to prepare molecular libraries. 
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The Martin group has had a longstanding interest in the synthesis of alkaloid 
natural products.44 Through this interest, we have developed a multi-component assembly 
process that has allowed access to several related natural products. Extending this 
methodology from natural product synthesis to DOS has led to the synthesis of a variety 
of drug-like scaffolds that are highly diversifiable. Most notably, this methodology has 
lead to the synthesis of subtype selective sigma receptor ligands, which have shown 
significant promise as potential tool compounds that may be used to identify the sigma 2 
receptor.  By judicious manipulations of the MCAP methodology, we hope to thoroughly 
probe regions of chemical space that have been identified as regions of great promise for 
tool compounds for biological interrogation, and potential therapeutics. 
2.1.1  APPLICATIONS OF MCAPS FOR ACCESS TO ALKALOID NATURAL PRODUCTS 
 
In the late 1980’s, the Martin group utilized an MCAP as part of a unified strategy 
to access indole alkaloids of the yohimboid, heteroyohimboid, and corynantheoid 
classes.45,46 In the synthesis of oxogambirtannine (2.5), known dihydro-β-carboline 2.1 
was treated sequentially with acid chloride 2.2 and vinyl ketene acetal 2.3 in a three-
component assembly process that provided intramolecular Diels-Alder substrate 2.4. The 
Diels-Alder reaction was carried out in the presence of benzoquinone to promote 
oxidation after the spontaneous extrusion of CO2 to yield oxogambirtannine (53) in only 
three steps (Scheme 2.1). 
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Scheme 2.1: The Martin group’s total synthesis of oxogambirtannine (2.5) 
 
The efficiency of this three-component assembly process was further exemplified 
for access to related indole alkaloids tetrahydroalstonine (2.10) and geissoschizine (2.11). 
This divergent synthesis utilized a similar three-component assembly process followed by 
an intramolecular hetero-Diels-Alder reaction to give common intermediate 2.9, which 
was elaborated to tetrahydroalstonine (2.10) in two steps and geissoschizine (2.11) in 
three steps (Scheme 2.2).  
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Scheme 2.2: The Martin group’s total syntheses of tetrahydroalstonine (2.10) and 
geissoschizine (2.11). 
 
Recognizing the power of the three-component assembly process for quickly synthesizing 
alkaloid natural products, the Martin group became interested in probing the full scope of 
this strategy.44,47-49 As a result of these efforts, the Martin group published a cascade 
iminium ion cyclization approach to the synthesis of quinolizidines, including natural 
products (±)-epilupinine and (-)-epimyrtine.50 The sequence of reactions commenced with 
the condensation of amino allylsilane 2.12 with monoprotected dialdehyde 2.13 to 
generate imine 2.15. Upon addition of acid, 2.15 cyclized to give iminium ion 2.16, 
which underwent nucleophilic attack by the allylsilane moiety to give N,O-acetal 2.17. 
Ionization of the alkoxy group in 2.17 would produce another iminium ion that could be 
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trapped by many different nucleophiles to provide a number of different fused bicyclic 
amines of the general type 2.14 (Scheme 2.3). 
Scheme 2.3: Iminium ion cyclization cascade 
 
 
A simple variation of the amino allylsilane from the linear analog 2.12 to the branched 
compound 2.15 offers additional entry points to these bicyclic systems of the general type 
2.20 (Equation 2.1). 
 
While the individual steps outlined in Scheme 6 were known, they had never been 
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significantly higher increase in structural complexity in a single operation than any of the 
precedented reactions that made up its parts. The total syntheses of (±)-epilupinine (2.25) 
and (–)-epimyrtine (2.24) showcased the iminium ion cascade reactions by quickly 
accessing fused bicyclic amines. In the total synthesis of (±)-epilupinine (2.25), amino 
allylsilane 2.21 was condensed with the monoprotected dialdehyde 2.22. The resulting 
imine was then treated with trifluoroacetic acid (TFA) without being isolated, initiating 
the two acid catalyzed cyclizations that generated the iminium ion 2.23. Reduction of 
2.23 with triethylsilane gave 2.24 as a single diastereomer in 75% yield from 2.21. 
Ozonolysis of the trifluoroacetate salt of 2.24 followed by reduction of the intermediate 
ozonide provided (±)-epilupinine (2.25) in 88% yield (Scheme 2.4). 
Scheme 2.4: Total Synthesis of (±)-Epilupinine (2.25) 
 
The total synthesis of (–)-epimyrtine (2.24) also proceeded effectively utilizing the 
strategy outlined in Equation 4. The synthesis began with the condensation of chiral 
amino allylsilane 2.26 with aldehyde 2.22 to give an imine that was treated sequentially 
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with trifluoroacetic acid and sodium cyanide to give quinolizidine 2.27 in 90% yield. 
Reduction of the aminonitrile moiety of 2.27 yielded an epimeric mixture (95:5) of 
quinolizidines 2.28a,b. Ozonolysis of the trifluoroacetate salt of 2.28a,b yielded an 
inseparable mixture (95:5) of (–)-epimyrtine (2.24) and (+)-myrtine (2.25) (Scheme 2.5). 
Scheme 2.5: Total Synthesis of (–)-Epimyrtine (2.24) 
 
The opportunity to trap iminium ions resulting from the collapse of the N,O-acetal in 
intermediates of the general type 2.17 presents an exciting opportunity to further build 
complexity into the scaffolds accessed via this iminium ion cascade. This concept was 
brought to fruition with the synthesis of spirocyclic tricycle 2.30. Amino allylsilane 2.26 
was condensed with aldehyde 2.22, where upon trifluoroacetic acid and sodium cyanide 
were added sequentially to furnish an epimeric mixture (88:12) of amino nitriles 2.27a,b 
in 89% yield. Quantitative deprotonation of 2.27a,b followed by addition of tosylate 2.28 
provided 2.29 in 62% yield. Finally, treatment of 2.29 with AgOTf formed an iminium 
ion, that was trapped by an intramolecular cyclization of the allylsilane to provide the 
spirocyclic tricycle 2.30 in 81% yield (Scheme 2.6). 
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Scheme 2.6: Use of Amino Nitrile to Access a Spirocyclic Tricycle 
 
In summary, the Martin group’s interest in the synthesis of natural products has 
lead to the discovery of several MCAPs and related reactions, each lending themselves to 
the preparation of a unique array of biologically pre-validated scaffolds. Most 
importantly, these syntheses demonstrate the impressive amount of molecular complexity 
attainable in a single, modular transformation via MCAP strategies. 
2.1.2  APPLICATIONS OF MCAPS FOR THE SYNTHESIS OF MOLECULAR LIBRARIES 
 
 
The success of the MCAP methodology for accessing a series of structurally 
related natural products suggested the technique could be applied to the concise synthesis 
of a library of small molecules. Such a strategy would combine aspects of BIOS and DOS 
to generate multiple large collections of diverse compounds containing components of 
biologically pre-validated structures. In a four-component assembly process, we 
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envisioned an aryl aldehyde 2.31 reacting first with an amine 2.32 to give an intermediate 
imine that then reacts with an acylating or alkylating agent 2.33 followed by a 
nucleophile 2.34 to provide aryl aminomethyl derivative 2.35. It is important to note that 
the aryl aminomethyl motif accessed by this MCAP is very common in natural products 
and other medicinally relevant small molecules.53 Including additional functional handles 
in the original four components of the MCAP allows 2.35 to undergo various 
intramolecular cyclization reactions to access even more complex scaffolds of the type 
2.36. Even further diversification of this variety of scaffolds via orthogonal functional 
handles that remain after the series of intramolecular cyclizations provides large 
collections of diverse compounds 2.37 (Scheme 2.7). 
Scheme 2.7: General overview of the original Martin group MCAP strategy 
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 Since the goal of this project was to quickly access diverse libraries of 
biologically pre-validated scaffolds, we turned our attention towards the application of 
this methodology to the synthesis of piperidine and homopiperdine ring systems, which 
are well represented subunits of both biologically active natural products and 
pharmaceutical agents.39,54,55 The potential applications of this idea were demonstrated by 
condensing aryl aldehyde 2.38 with allylamine, followed by sequential treatment with 
acetyl chloride and allylzinc bromide to give the aryl aminomethyl moiety 2.39 in 82% 
yield. Ring closing metathesis of diene 2.39 with Grubb’s II catalyst 2.41 and subsequent 
Dieckmann cyclization afforded benzazepine 2.40 in 70% yield (Scheme 2.8). 
Scheme 2.8: MCAP/RCM/Dieckmann Cyclization Sequence 
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topographies. In this case, 2-bromobenzaldehyde (2.43) was condensed with allylamine, 
and the resultant imine was sequentially treated with phenylacetyl chloride and allylzinc 
bromide to give diene 2.44 in 85% yield. Ring closing metathesis with Hoveyda-Grubb’s 
II 2.42 followed by an intramolecular Heck reaction afforded norbenzomorphan 2.45 in 
65% yield (Scheme 2.9) 
Scheme 2.9: MCAP/RCM/Intramolecular Heck Sequence 
 
 Compound 2.45 is a member of the norbenzomorphan structural family. The 
norbenzomorphan structure 2.48 was first synthesized in the 1960’s and is related to 
benzomorphan (2.47), a structural subunit of morphine (2.46). Derivatives of 
norbenzomorphan have been found to have a wide range of therapeutically relevant 
activities, and structures closely related to norbenzomorphan 2.48 have been incorporated 
into the FDA approved psychoactive drugs Talwin® (2.49) and Chantix® (2.50) (Figure 
2.1).56,57 
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Figure 2.1: The Norbenzomorphan Subunit and Related Structures Found in Morphine 
(2.46) and Psychoactive Drugs Talwin® (2.49) and Chantix® (2.50). 
 
 Considering the presence of the norbenzomorphan subunit and closely related 
chemical structures in biologically active compounds,58,59 we decided to take advantage of 
the quick access to this chemical space that our MCAP offered by creating a library of 
derivatives based off the general structure 2.48. The strategy proved to be quite useful, 
whereby 2,4-, 2,5-, and 2,6-dihalobenzaldehydes of the general type 2.51 were treated 
with allylamine, benzyl chloroformate, and allylzinc bromide to give dienes of the 
general type 2.52. These dienes were cyclized by sequential ring closing metathesis and 
intramolecular Heck reactions, followed by reduction of the remaining double bond to 
give saturated norbenzomorphans of the general type 2.53 (Scheme 2.10).56 
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Scheme 2.10: Approach to a Diverse Library of Norbenzomorphans 
 
 The norbenzomorphans 2.45 were then derivatized via cross-coupling the aryl 
chloride moiety with various amines and boronic acids to give substituted 
norbenzomorphans of the general type 2.55 (Equation 2.2).  
 
Notably, norbenzomorphans 2.54 and 2.55 could be transformed to the tertiary 
benzylamine 2.56 in a single step via deprotection with TMSI, followed by treatment 
with base.60 Quaternization was never observed when amines were benzylated by this 
method (Equation 2.3).  
 
Treatment of norbenzomorphans of the general type 2.54 or 2.55 with TMSI 
followed by an acidic workup afforded secondary amines 2.57 that were derivatized into 
a variety of N-substituted norbenzomorphans of the general type 2.58 (Scheme 2.11). 
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Scheme 2.11: Amine Refunctionalization for the Assembly of a Library of 
Norbenzomorphans 
 
The NIH’s Molecular Library Probe Production Center Network (MLPCN), the 
National Institute of Mental Health’s (NIMH) Psychoactive Drug Screening Program 
(PDSP), and Eli Lilly’s OPEN Innovation Drug Discovery (OIDD) Program, screened 
the initial library of 124 compounds for biological activity.56 While several biologically 
active compounds were identified, the most interesting compounds were those with high 
affinity and subtype selectivity for sigma receptors,61 an activity that has not previously 
been associated with norbenzomorphans.57 
Sigma receptors are a distinct class of non-G protein-coupled receptor (GPCR) 
receptors that are involved in a variety of critical cellular processes, including regulation 
of ion channel concentration, stabilization of cell-surface receptors, and induction of 
apoptosis.62 Two receptor subtypes, the sigma 1 receptor (Sig1R), and the sigma 2 
receptor (Sig2R), have been identified. While Sig1R has been cloned, sequenced, and 
crystallized,63 Sig2R has only been characterized by radioligand binding assays. In spite 
of this, Sig2R has been implicated in a number of disease states.64,65 For example, Sig2R 
is overexpressed in cancer cells, making the protein an attractive target for cancer 
diagnostics and therapeutics. This interest is expanding into the realm of 
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chemotherapeutics because Sig2R agonists have been shown to induce cell death in a 
number of cancer cell lines.  
While many compounds have high affinity for sigma receptors, there are not 
many tool compounds available that selectively target Sig2R over Sig1R. Such a 
compound is important for efforts to isolate, sequence, and eventually crystallize Sig2R. 
It is noteworthy then, that the further diversification of the original 124-member library 
of substituted norbenzomorphans yielded compound 2.59, which displays a 574-fold 
preference for Sig2R over Sig1R (Figure 2.2).57 Efforts to utilize the remarkable level of 
selectivity of compounds related to 2.59 as tools for the isolation and characterization of 
Sig2R are underway. 
Figure 2.2: A Norbenzomorphan with High Selectivity for the Sigma 2 Receptor 
 
 The success of our library of norbenzomorphans made us eager to find related 
chemical spaces that MCAP methodology would allow us to access. For this reason, 
piperidines containing exocyclic double bonds of the general type 2.62 caught our 
interest. While an intramolecular Heck reaction using compounds of the general type 2.60 
gives access to norbenzomorphans of the general type 2.61 (Equation 2.4), a reductive 
N
CbzN
NEtO
O
2.59
Sig1R Ki = 9294 nM
Sig2R Ki = 16.2 nM
Sig1R Ki/Sig2R Ki = 574
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intramolecular Heck reaction using compounds of the general type 2.62 would offer 
access to norbenzomorphans of the general type 2.63 (Equation 2.5). 
 
 
Not only does this approach incorporate a new quaternary center into the already 
biologically validated norbenzomorphan scaffold, but ozonolysis of the exocyclic double 
bond in compounds of the general type 2.64 could give ketones of the general type 2.65, 
creating an opportunity to cyclize via lithium halogen exchange to give compounds 2.66. 
Additionally, we believe the aryl ring in compounds 2.64 and 2.65 is preferentially 
oriented in the axial position on the piperidine ring in order to avoid A1,3 strain resulting 
from interactions of the aryl group with the carbamate moiety. Thus, selective reduction 
from the least hindered face of ketones of the general type 2.65 should give alcohols syn 
to the aryl ring, allowing for an intramolecular Ullman reaction to give oxygenated 
benzomorphans of the general type 2.68 (Scheme 2.12).66 
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Scheme 2.12: Other Potential Scaffolds Accessible via Piperidines of the General Type 
2.64 
 
 In addition to potentially allowing access to the scaffolds in Scheme 15, 
compounds of the general type 2.64 contain a piperidine ring, the most well represented 
nitrogen heterocycle in FDA approved pharmaceuticals.67 With this in mind, as well as 
our hopes to access the scaffolds outlined in Schemes 12 and 14 in such a way that 
several derivatives of each can be easily prepared, we decided to find a method by which 
we could access an array of piperidines of the general subtype 2.64. 
 Such a route would allow easy variation of the substitution on the aryl ring, as 
well as allowing easy manipulations of nitrogen atom functionality. We envisioned that 
by incorporating amine 2.69 into the MCAP procedure outlined in Scheme 9, we could 
access imines of the general type 2.71. Formation of the iminium ion via protic or Lewis 
acids is known to initiate cyclization of the allylsilane to give 2-arylpiperidine 2.72 
(Scheme 16). 50,51,68 While this cyclization is known, its potential application to DOS is 
yet to be explored, and with the aryl aminomethyl and piperidine subunits being so well 
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represented in pharmaceutical compounds and natural products, the creation of a library 
of compounds related to 2.72, as well as their elaboration to more complex scaffolds, 
represent an opportunity to further explore promising chemical space. 
Scheme 2.13: General Approach to Piperidines of the General Type 2.72 
 
 Mechanistically, this cyclization is proposed to proceed by first forming the 
iminium ion 2.73.50,51 The allylsilane then adds into the iminium ion to give carbocation 
2.74. This intermediate undergoes elimination to provide the secondary amine 2.75 
(Scheme 17). 
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Scheme 2.14: Mechanism of Iminium Ion Cyclization 
 
2.2 Results and Discussion 
 With the goal of creating a library of 2-arylpiperidines in mind, we first sought to 
establish a standard procedure by which all piperidines of the general type 2.72 would be 
synthesized. As part of an effort to synthesize compounds of the general type 2.68, Dr. 
James Sahn had already established preliminary conditions for the cyclization of imine 
2.77 to give 2-arylpiperidine 2.75a. In this procedure 2-bromobenzaldehyde (2.31a) was 
condensed with amine 2.69 using 4 Å molecular sieves. The resultant imine was treated 
with one equivalent of trifluoroacetic acid (TFA) at 0 °C to give the 2-arylpiperidine in 
34% yield (Scheme 2.15). 
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Scheme 2.15: Initial Procedure for the Synthesis of Compound 2.75a via Iminium Ion 
Cyclization 
 
 While repeating Dr. Sahns work, it was found that intermediate imine 2.77 was 
being formed in roughly a 4:1 ratio of isomers, presumed to be the trans and cis isomers, 
respectively. We rationalized that the cis isomer would undergo cyclization less readily 
than the trans isomer because the transition state of the cis iminium ion would result in 
steric clash between the allylsilane moiety and the arene ring (Figure 8). 
Figure 2.3: Comparison of the Transition States of the trans Isomer 2.73a cis Isomer 
2.73b of Iminium Ion  
 
We found that cooling a solution of 2-bromobenzaldehyde (2.31a) in DCM to 0 °C and 
adding amine 2.69 dropwise in the presence of MgSO4 before allowing the reaction to 
warm to room temperature, provided isomerically pure 2.77 after two hours. We then 
found that adding one equivalent of TFA to a solution of 2.77 in MeCN at 0 °C, followed 
by a basic workup and purification via flash column chromatography provided compound 
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2.75a in 66% yield. This result suggests that the trans imine undergoes cyclization more 
readily than the cis imine, which aligns with our understanding of the mechanism of this 
reaction. These conditions were used as the standard procedure for this transformation, 
however, the imine was not typically isolated and characterized in subsequent 
experiments. No further efforts to optimize the cyclization reaction via changes in 
solvent, temperature, or proton source were made (Scheme 2.16). 
Scheme 2.16: Optimized Procedure for the Synthesis of Compound 2.75a via Iminium 
Ion Cyclization 
 This procedure was then applied to the synthesis of a series of 2-arylpiperidines 
2.75a–h. The yields were uniformly in the range of 50-70%, allowing us access to 100 
mg quantities of each compound for further derivatization. 
 
 
 
 
 
 
O
Br
2.69, MgSO4,
DCM,
0 °C to r.t.
2 h
N
Br
TMS
TFA, MeCN,
0 °C, 0.5 h
66% Br
HN
2.31a
2.77
2.75a
 46 
Table 2.1: 2-Arylpiperidines synthesized via Iminium Ion Cyclization Strategy 
 
 
 With access to 2-arylpiperidines 2.75a–h established, we set out to derivatize the 
compounds via a series of N-functionalizations. Ideally, we hoped to alkylate, tosylate, or 
acylate the amine in high yield and with minimal purification.  
In preliminary experiments, we found that methylation of 2.75 could be carried 
out via reductive amination with formaldehyde and formic acid in water under 
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 47 
microwave heating in about 10 minutes. This procedure provided tertiary amine 2.78a in 
60% yield and greater than 90% purity by 1H NMR (Equation 2.6).  
 
 While this microwave procedure was convenient, the yield was significantly 
lower than we thought acceptable. Changing the reducing agent from formic acid to 
NaBH3CN and running the reaction at room temperature with no microwave heating 
provided tertiary amine 2.78a in 80% yield after two hours. Having found conditions that 
provided compound 2.78a in acceptable yields, we applied these conditions to the 
synthesis of compounds 2.78b–h. The results of these experiments are outlined in Table 
2.2. 
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Table 2.2: 2-Arylpiperidines Prepared via Reductive Alkylation of Compounds 2.75a–h 
 
Acylation was carried out by treating a solution of amine 2.75a and 
diisopropylethylamine (DIPEA) with two equivalents of acetyl chloride (AcCl) at 0 °C, 
followed by stirring overnight at room temperature. Purification of the crude material by 
flash column chromatography afforded amide 2.79a in 85% yield (Equation 11). The 
conditions were then applied to the synthesis of compounds 2.79b–h, accordingly. These 
results are outlined in Table 2.3.  
OMe
OMe
OMe
MeO
OMe
MeO
FBr
Cl
Cl
O
O
Br
S
a
c
b
d
e
f
g
h
Yield (%)* Yield (%)*
88
66
94
94
74
59
94
92
Aryl GroupEntry Entry Aryl Group
* Isolated yields of compounds >90% pure by 1H NMR
Ar
HN H2CO, NaBH3CN,
MeCN
r.t., 2 h
Ar
N
Me
2.75a–h 2.78a–h
 49 
Table 2.3: Synthesis of N-Acylpiperidines via Acylation of Compounds 2.75a–h 
 
Finally, tosylation was accomplished by treating a solution of amine 2.75a and 
triethylamine (TEA) in DCM with two equivalents of toluenesulfonyl chloride (TsCl) at 0 
°C and then allowing this solution to warm to room temperature. Purification by flash 
column chromatography was avoided by adding 10 equivalents of pyridine in order to 
catalyze the hydrolysis of excess toluenesulfonyl chloride. Subsequent acid/base 
purification provided sulfonamide 2.79a in 94% yield (Equation 12). With satisfactory N-
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tosylation conditions established, we synthesized sulfonamides 2.80b–h. The results of 
this effort are outlined in Table 2.4. 
Table 2.4: Synthesis of Sulfonomides via Tosylation of Compounds 2.75a–h 
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2.3 Summary 
 
In summary, we have developed a novel iminium ion formation and cyclization 
cascade of reactions and applied it to the synthesis of a library of highly diversifiable 2-
aryl piperidines in good overall yield. The N-functionalization reactions were all easily 
carried out, thereby permitting the quick assembly of the library. It is noteworthy that the 
aryl aminomethyl subunit present in all of the compounds synthesized is a common 
structural motif found in biologically active small molecules,53 and the reactions used to 
prepare each individual compound were metal-free and utilized inexpensive, common 
laboratory reagents. Additionally, while the 2-arylpiperidines synthesized already contain 
biologically relevant substructures, the use of 2-halobenzaldehydes of the general type 
2.31a also gives access to compounds that may prove to be valuable intermediates in the 
synthesis of new norbenzomorphan compounds (Equations 7 and 8, Scheme 15). This is 
particularly noteworthy given that the Martin lab has already shown the 
norbenzomorphan scaffold to have unusual biological activity in the context of the sigma 
receptors.56,57 
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CHAPTER 3:  EXPERIMENTAL METHODS 
 General. Tetrahydrofuran and diethyl ether were dried by filtration through two 
columns of activated, neutral alumina according to the procedure described by Grubbs.63 
Methanol, acetonitrile and dimethylformamide were dried by filtration through two 
columns of activated molecular sieves, and toluene was dried by filtration through one 
column of activated, neutral alumina followed by one column of Q5 reactant.  Methylene 
chloride, diisopropylamine, triethylamine, and diisopropylethylamine were distilled from 
calcium hydride immediately prior to use.  Pyridine was distilled from potassium 
hydroxide (KOH) and calcium hydride. All reagents were reagent grade and used without 
purification unless otherwise noted. All reactions involving air or moisture sensitive 
reagents or intermediates were performed under an inert atmosphere of nitrogen or argon 
in glassware that was flame dried.  Reaction temperatures refer to the temperature of the 
cooling/heating bath. Volatile solvents were removed under reduced pressure using a 
Büchi rotary evaporator at 25–30 °C. Chromatography was performed using forced flow 
(flash chromatography) and the indicated solvent system on Silicycle SiliaFlash F60 (40-
63μ). Proton nuclear magnetic resonance (1H NMR) and carbon nuclear magnetic 
resonance (13C NMR) spectra were obtained at the indicated field as solutions in CDCl3 
unless otherwise indicated.  Chemical shifts are referenced to the deuterated solvent and 
are reported in parts per million (ppm, δ) downfield from tetramethylsilane (TMS, δ = 
0.00 ppm).  Coupling constants (J) are reported in Hz and the splitting abbreviations used 
are: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; comp, overlapping multiplets 
of magnetically nonequivalent protons; br, broad; app, apparent. 
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Ethyl (1S,2S)-1-((S)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxyphenyl) 
propanamido)-2-ethylcyclopropane-1-carboxylate (1.38). A solution of compound 
1.37 (337 mg, 2.1 mmol), N-boc-tyrosine (603 mg, 2.1 mmol), EDCI•HCl (460 mg, 2.4 
mmol), and Oxyma (611 mg, 4.3 mmol) in DMF (8.4 mL) was cooled to 0 °C and N-
methylmorpholine (707 μL, 6.4 mmol) was added to the solution via syringe. The 
reaction stirred at room temperature until the starting material had been consumed 
(LC/MS). The reaction was concentrated and the resulting residue was dissolved in ethyl 
acetate (20 mL) and washed with 0.1 M HCl (3 x 10 mL) and saturated NaHCO3 (3 x 10 
mL). The organic solution was then dried over MgSO4, and concentrated. The resulting 
residue was purified via flash column chromatography to yield 585 mg (67%) of 1.38: 1H 
NMR (400 MHz; CDCl3): δ  7.08 (d, J = 8.2 Hz, 2 H), 6.72 (d, J = 8.2 Hz, 2 H), 6.37 (br 
s, 1 H), 5.14 (br s, 1 H), 4.31-4.30 (q, 1 H), 4.13-4.08 (comp, 2 H), 3.01 (comp, 2 H), 
1.70-1.66 (comp, 2 H), 1.46-1.44 (comp, 11 H), 1.20 (t, J = 7.1 Hz, 3 H), 1.05-1.03 (m, 1 
H), 0.94 (t, J = 7.2 Hz, 3 H), 0.74 (dd, J = 6.7, 4.2 Hz, 1 H). 13C-NMR (101 MHz): δ  
173.0, 172.3, 155.8, 155.1, 130.7, 128.4, 115.6, 105.2, 61.5, 55.8, 37.8, 37.1, 30.1, 28.4, 
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22.8, 21.7, 14.3, 13.5. HRMS (ESI) m/z calcd for C22 H32N2O6 (M+Na)+, 443.2153; found, 
443.2164 
NMR Assignments. For 1.38: 1HNMR (400 MHz; CDCl3): δ  7.08 (d, J = 8.2 
Hz, 2 H, C8-H), 6.72 (d, J = 8.2 Hz, 2 H, C9-H), 6.37 (br s, 1 H, N13-H), 5.14 (br s, 1 H, 
C11-H), 4.31 (q, 1 H, C5-H), 4.13-4.08 (comp, 2 H, C20-H), 3.01 (comp, 2 H, C6-H), 
1.70-1.66 (comp, 2 H, C17-H), 1.46-1.44 (comp, 11 H, C1-H, C15-H), 1.20 (t, J = 7.1 
Hz, 3 H, C21-H), 1.05-1.03 (m, 1 H, N4-H), 0.94 (t, J = 7.2 Hz, 3 H, C18-H), 0.74 (dd, J 
= 6.7, 4.2 Hz, 1 H, C16-H). 13C-NMR (101 MHz): δ  173.0 (C19), 172.3 (C12), 155.8 
(C10), 155.1 (C3), 130.7 (C8), 128.4 (C7), 115.6 (C9), 105.2 (C20), 61.5 (C2), 55.8 (C5), 
37.8 (C21), 37.1 (C14), 30.1 (C6), 28.4 (C16), 22.8 (C1), 21.7 (C15), 14.3 (C18), 13.5 
(C17). 
 
(1S,2S)-1-((S)-2-((tert-Butoxycarbonyl)amino)-3-(4-
hydroxyphenyl)propanamido)-2-ethylcyclopropane-1-carboxylic acid (1.39). To a 
solution of compound 1.38 (116 mg, 0.28 mmol) in 2:1:1 THF : water : methanol (0.55 
mL) was added LiOH monohydrate (58 mg, 1.4 mmol). The resulting suspension was 
stirred at room temperature for 16 h before being diluted with water (5 mL) and washed 
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with ethyl acetate (5 mL). The aqueos solution was then acidified to a pH of ~2 with 0.1 
M HCl and extracted with ethyl acetate (3 x 10 mL). The organic solution was dried over 
MgSO4 and concentrated to yield 90 mg (83%) of compound 1.39 as a white solid. This 
material was used in the next step without further purification. 
 
 
tert-Butyl ((S)-1-(((1S,2S)-1-(((S)-1,4-diamino-1,4-dioxobutan-2-
yl)carbamoyl)-2-ethylcyclopropyl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-
yl)carbamate (1.41). A solution of compound 1.39 (710 mg, 1.8 mmol), EDCI•HCl (382 
mg, 2.0 mmol), Oxyma (515 mg, 3.6 mmol), and L-asparagine-amide (261 mg, 2.0 
mmol) in DMF (1.8 mL) was cooled to 0 °C and N-methylmorpholine (995 μL, 9.1 
mmol) was added via syringe. The reaction was stirred until the starting material was no 
longer present (TLC) and the solution was concentrated to give an orange residue which 
was purified via flash column chromatography to give 67 mg of compound 1.41 (7%) as 
a white solid. 1H-NMR (400 MHz; CD3OD): δ  7.07 (d, J = 8.4 Hz, 2 H), 6.70 (d, J = 8.4 
Hz, 2 H), 4.55 (t, J = 6.2 Hz, 1 H), 4.19 (t, J = 7.6 Hz, 1 H), 3.00-2.74 (comp, 4 H), 1.74-
1.66 (m, 1 H), 1.41 (comp, 11 H), 0.92 (t, J = 7.3 Hz, 3 H), 0.67 (m, 1 H), 0.56 (dd, J = 
7.2, 4.8 Hz, 1 H).	 13C NMR (126 MHz, CD3OD) δ 175.8, 174.3, 174.2, 172.7, 156.8, 
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156.0, 130.0, 127.4, 114.8, 79.6, 56.5, 50.9, 39.0, 35.8, 28.4, 27.34, 20.9, 12.4. HRMS 
(ESI) m/z calcd for C24H35N5O7 (M+Na)+, 528.2429; found, 528.2434 
 NMR Assignments. For 1.41: 1H-NMR (400 MHz; CD3OD): δ  7.07 (d, J = 8.4 
Hz, 2 H, C8-H), 6.70 (d, J = 8.4 Hz, 2 H, C9-H), 4.55 (t, J = 6.2 Hz, 1 H, C5-H), 4.19 (t, 
J = 7.6 Hz, 1 H, C21-H), 3.00-2.74 (comp, 4 H, C6-H, C22-H), 1.74-1.66 (m, 1 H, C16-
H), 1.41 (comp, 11 H, C1-H, C17-H), 0.92 (t, J = 7.3 Hz, 3 H, C18-H), 0.67 (m, 1 H, 
C15-H), 0.56 (dd, J = 7.2, 4.8 Hz, 1 H, C15-H). 13C NMR (126 MHz, CD3OD) δ 175.8 
(C24), 174.3 (C23), 174.2 (C19), 172.7 (C12), 156.8 (C10), 156.0 (C3), 130.0 (C8), 
127.4 (C7), 114.8 (C9), 79.6 (C2), 56.5 (C5), 50.9 (C21), 39.0 (C14), 35.8 (C6, C22), 
28.4 (C16), 27.4 (C1), 20.9 (C15), 12.4 (C18). 
 
Representative procedure for the synthesis of 2-arylpiperidines: 
 
 
2-(2-Bromophenyl)-4-methylenepiperidine (2.75a). A solution of 2-
bromobenzaldehyde (2.31a) (150 μL, 235 mg, 1.27 mmol) in dichloromethane (20 mL) 
containing MgSO4 (2 g) was cooled to 0 °C, and 3-((trimethylsilyl)methyl)but-3-en-1-
amine (2.69) (200 mg, 1.27 mmol) was added dropwise via syringe. The ice-bath was 
removed, and the reaction was stirred at room temperature for 2 h, at which point the 
MgSO4 was removed by vacuum filtration, and the solvent removed under reduced 
pressure. The crude residue was dissolved in anhydrous acetonitrile (25 mL), and the 
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resulting solution was cooled to 0°C. Trifluoroacetic acid (100 μL, 145 mg, 1.27 mmol) 
was added to this solution dropwise via syringe, and the reaction stirred at 0 °C for 0.5 h, 
at which point a saturated solution of NaHCO3 (5 mL) was added. This biphasic mixture 
was transferred to a separatory funnel with ethyl acetate (25 mL) and distilled water (10 
mL) and the layers were separated. The organic layer was dried (MgSO4) and the solvent 
removed under reduced pressure. The residue was purified via column chromatography, 
eluting with hexanes/ethyl acetate (2:1) to give 211 mg (53%) of compound 2.75a as a 
clear oil. 1H NMR (400 MHz, CDCl3) δ 7.59 (dd, J = 7.8, 1.8 Hz, 1 H), 7.53 (dd, J = 8.0, 
1.3 Hz, 1 H), 7.31 (td, J = 7.6, 1.3 Hz, 1 H), 7.11 (td, J = 8.0, 7.3, 1.8 Hz, 1 H), 4.78 – 
4.75 (comp, 2 H), 3.99 (dd, J = 11.2, 2.8 Hz, 1 H), 3.31 – 3.23 (m, 1 H), 2.85 – 2.75 (m, 1 
H), 2.52 (ddd, J = 12.9, 2.8, 0.9 Hz, 1 H), 2.34 – 2.25 (m, 2 H), 2.15 – 2.06 (m, 1 H), 1.77 
(br s, 1 H). 13C NMR (101 MHz, CDCl3) δ 146.1, 142.9, 132.8, 128.6, 127.80, 127.7, 
123.3, 108.7, 61.3, 48.1, 41.9, 34.8. HRMS (ESI) m/z calcd for C12 H14BrN (M+H)+, 
252.0382; found, 252.0389 
NMR assignments. For 2.75a: 1H NMR (400 MHz, CDCl3) δ 7.59 (dd, J = 7.8, 
1.8 Hz, 1 H, C3-H), 7.53 (dd, J = 8.0, 1.3 Hz, 1 H, C6-H), 7.31 (td, J = 7.6, 1.3 Hz, 1 H, 
C4-H), 7.11 (td, J = 7.3, 1.8 Hz, 1 H, C5-H), 4.78 – 4.75 (comp, 2 H, C10-H2), 3.99 (dd, 
J = 11.2, 2.8 Hz, 1 H, C7-H), 3.31 – 3.23 (m, 1 H, C12-Heq), 2.85 – 2.75 (m, 1 H, C12-
Hax), 2.52 (ddd, J = 12.9, 2.8, 0.9 Hz, 1 H, C8-Heq), 2.34 – 2.25 (comp, 2 H, C11-Heq and 
C11-Hax), 2.15 – 2.06 (m, 1 H, C8-Hax), 1.77 (br s, 1 H, N15-H). 13C NMR (101 MHz, 
CDCl3) δ 146.1 (C2), 142.9 (C1), 132.8 (C6), 128.6 (C5), 127.80 (C4), 127.7 (C3), 123.3 
(C10), 108.7 (C9), 61.3 (C7), 48.1 (C12), 41.9 (C8), 34.8 (C11). 
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 2-(2,3-Dimethoxyphenyl)-4-methylenepiperidine (2.75b). Prepared in accord 
with the representative procedure to yield 84 mg (56%) of the title compound as a clear 
oil. The crude product was purified by flash column chromatography, eluting with 
hexanes/ethyl acetate (1:1). 1H NMR (400 MHz, CDCl3) δ 7.08 – 7.02 (comp, 2 H), 6.83 
(dd, J = 6.5, 3.1 Hz, 1 H), 4.77 – 4.68 (comp, 2 H), 3.97 (dd, J = 11.3, 2.9 Hz, 1 H), 3.86 
(s, 3 H), 3.84 (s, 3 H), 3.30 – 3.21 (m, 1 H), 2.85 – 2.71 (m, 1 H), 2.45 – 2.37 (m, 1 H), 
2.30 – 2.22 (comp, 3 H), 2.00 (br s, 1 H). 13C NMR (101 MHz, CDCl3) δ 152.5, 146.8, 
146.4, 137.7, 124.2, 118.8, 111.2, 108.2, 61.1, 56.5, 55.8, 48.2, 42.7, 35.2. HRMS (ESI) 
m/z calcd for C14H19NO2 (M+H)+, 234.1489; found, 234.1481 
 NMR assignments. For 2.75b: 1H NMR (400 MHz, CDCl3) δ 7.08 – 7.02 (comp, 
2 H, C6-H and C5-H), 6.83 (dd, J = 6.5, 3.1 Hz, 1 H, C4-H), 4.77 – 4.68 (comp, 2 H, 
C12-H2), 3.97 (dd, J = 11.3, 2.9 Hz, 1 H, C9-H), 3.86 (s, 3 H, C7-H or C8-H), 3.84 (s, 3 
H, C7-H, C8-H), 3.30 – 3.21 (m, 1 H, C14-Heq), 2.85 – 2.71 (m, 1 H, C14-Hax), 2.45 – 
2.37 (m, 1 H, C10-Heq), 2.30 – 2.22 (comp, 3 H, C10-Hax and C13-Heq and C13-Hax), 2.00 
(br s, 1 H, N15-H). 13C NMR (101 MHz, CDCl3) δ 152.5 (C1), 146.8 (C2 or C3), 146.4 
(C2 or C3), 137.7 (C5 or C6), 124.2 (C5 or C6), 118.8 (C4), 111.2 (C12), 108.2 (C11), 
61.1 (C9), 56.5 (C7 or C8), 55.8 (C7 or C8), 48.2 (C14), 42.7 (C10), 35.2 (C13). 
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 2-(3,4-Dimethoxyphenyl)-4-methylenepiperidine (2.75c). Prepared in accord 
with the representative procedure to yield 57 mg (38%) of the title compound as an off 
white solid. The crude product was purified by flash column chromatography, eluting 
with hexanes/ethyl acetate (1:1); 1H NMR (400 MHz, CDCl3) δ 6.95 (d, J = 2.0 Hz, 1 H), 
6.89 (dd, J = 8.2, 2.0, 0.5 Hz, 1 H), 6.81 (d, J = 8.2 Hz, 1 H), 4.75 – 4.69 (comp, 2 H), 
3.89 (s, 3 H), 3.86 (s, 3 H), 3.53 (dd, J = 11.3, 2.9 Hz, 1 H), 3.29 – 3.21 (m, 1 H), 2.80 – 
2.68 (m, 1 H), 2.38 (dd, J = 13.0, 2.9 Hz, 1 H), 2.30 – 2.21 (comp, 3 H), 1.97 (br s, 1 H). 
13C NMR (101 MHz, CDCl3) δ 149.0, 148.2, 146.6, 137.2, 118.6, 111.0, 109.7, 108.3, 
62.9, 55.9, 55.9, 48.1, 44.0, 34.9. HRMS (ESI) m/z calcd for C14H19NO2 (M+H)+, 
234.1489; found, 234.1492 
 NMR assignments. For 2.75c: 1H NMR (400 MHz, CDCl3) δ 6.95 (d, J = 2.0 Hz, 
1 H, C2-H), 6.89 (dd, J = 8.2, 2.0, 0.5 Hz, 1 H, C6-H), 6.81 (d, J = 8.2 Hz, 1 H, C5-H), 
4.75 – 4.69 (comp, 2 H, C12-H2), 3.89 (s, 3 H, C7-H or C8-H), 3.86 (s, 3 H, C7-H or C8-
H), 3.53 (dd, J = 11.3, 2.9 Hz, 1 H, C9-H), 3.29 – 3.21 (m, 1 H, C14-Heq), 2.80 – 2.68 (m, 
1 H, C14-Heq), 2.38 (dd, J = 13.0, 2.9 Hz, 1 H, C10-Heq), 2.30 – 2.21 (comp, 3 H, C10-Hax 
and C13-Heq and C13-Hax), 1.97 (br s, 1 H, N15-H). 13C NMR (101 MHz, CDCl3) δ 149.0 
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(C1), 148.2 (C3 or C4), 146.6 (C3 or C4), 137.2 (C6), 118.6 (C2 or C5), 111.0 (C2 or 
C5), 109.7 (C12), 108.3 (C11), 62.9 (C9), 55.90 (C7 or C8), 55.88 (C7 or C8), 48.1 
(C14), 44.0 (C10), 34.9 (C13). 
 
 
 
 2-(2,5-Dimethoxyphenyl)-4-methylenepiperidine (2.75d). Prepared in accord 
with the representative procedure to yield 79 mg (53%) of the title compound as an off 
white solid. The crude product was purified by flash column chromatography, eluting 
with hexanes/ethyl acetate (1:1); 1H NMR (400 MHz, CDCl3) δ 7.03 (d, J = 3.0 Hz, 1 H), 
6.79 (d, J = 8.8 Hz, 1 H), 6.74 (dd, J = 8.8, 3.0 Hz, 1 H), 4.76 – 4.70 (comp, 2 H), 3.93 
(dd, J = 11.3, 2.9 Hz, 1 H), 3.79 (s, 3 H), 3.77 (s, 3 H), 3.29 – 3.20 (m, 1 H), 2.82 – 2.70 
(m, 1 H), 2.43 (dd, J = 12.9, 2.9 Hz, 1 H), 2.31 – 2.19 (comp, 4 H), 2.05 (br s, 1 H). 13C 
NMR (101 MHz, CDCl3) δ 153.8, 150.8, 146.8, 133.2, 113.0, 112.4, 111.5, 108.2, 56.7, 
55.9, 55.8, 48.0, 41.6, 35.2. HRMS (ESI) m/z calcd for C14H19NO2 (M+H)+, 234.1489; 
found, 234.2489 
 NMR assignments. For 2.75d: 1H NMR (400 MHz, CDCl3) δ 7.03 (d, J = 3.0 
Hz, 1 H, C6-H), 6.79 (d, J = 8.8 Hz, 1 H, C3-H), 6.74 (dd, J = 8.8, 3.0 Hz, 1 H, C4-H), 
4.76 – 4.70 (comp, 2 H, C12-H), 3.93 (dd, J = 11.3, 2.9 Hz, 1 H, C9-H), 3.79 (s, 3 H (C7-
H or C8-H), 3.77 (s, 3 H, C7-H or C8-H), 3.29 – 3.20 (m, 1 H, C14-Heq), 2.82 – 2.70 (m, 
1 H, C14-Hax), 2.43 (dd, J = 12.9, 2.9 Hz, 1 H, C10-Heq), 2.31 – 2.19 (comp, 4 H, C10-Hax 
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and C13-Heq and C13-Hax), 2.05 (br s, 1 H, N15-H). 13C NMR (101 MHz, CDCl3) δ 153.8 
(C2 or C5), 150.8 (C2 or C5), 146.8 (C1), 133.2 (C6), 113.0 (C4 or C3), 112.4 (C4 or 
C3), 111.5 (C12), 108.2 (C11), 56.7 (C9), 55.9 (C7 or C8), 55.8 (C7 or C8), 48.0 (C14), 
41.6 (C10), 35.2 (C13). 
 
 
2-(4-Bromo-2-fluorophenyl)-4-methylenepiperidine (2.75e). Prepared in accord 
with the representative procedure to yield 111 mg (64%) of the title compound as a white 
solid. The crude product was purified by flash column chromatography, eluting with 
hexanes/ethyl acetate (1:1); 1H NMR (400 MHz, CDCl3) δ 7.39 (t, J = 8.0 Hz, 1 H), 7.28 
– 7.24 (m, 1 H), 7.19 (dd, J = 9.9, 1.9 Hz, 1 H), 4.77 – 4.71 (m, 2 H), 3.88 (dd, J = 11.3, 
2.9 Hz, 1 H), 3.25 (ddd, J = 11.4, 4.6, 2.9 Hz, 1 H), 2.82 – 2.68 (m, 1 H), 2.40 (ddd, J = 
13.0, 3.0, 1.1 Hz, 1 H), 2.31 – 2.21 (m, 2 H), 2.19 – 2.10 (m, 1 H), 1.76 (s, 1 H). 13C 
NMR (101 MHz, CDCl3) δ 159.9 (d, J = 250.6 Hz), 145.7, 130.4 (d, J = 13.4 Hz), 128.9 
(d, J = 5.6 Hz), 127.6 (d, J = 3.5 Hz), 120.7 (d, J = 9.9 Hz), 118.9 (d, J = 25.7 Hz), 108.9, 
55.4 (d, J = 2.0 Hz), 48.0, 42.2, 34.9. HRMS (ESI) m/z calcd for C12 H13BrFN (M+H)+, 
270.0288; found, 270.0297 
NMR assignments. For 2.75e: 1H NMR (400 MHz, CDCl3) δ 7.39 (t, J = 8.0 Hz, 
1 H, C6-H), 7.28 – 7.24 (m, 1 H, C5-H), 7.19 (dd, J = 9.9, 1.9 Hz, 1 H, C3-H), 4.77 – 
4.71 (m, 2 H, C10-H2), 3.88 (dd, J = 11.3, 2.9 Hz, 1 H, C7-H), 3.25 (ddd, J = 11.4, 4.6, 
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2.9 Hz, 1 H, C12-Heq), 2.82 – 2.68 (m, 1 H, C12-Hax), 2.40 (ddd, J = 13.0, 3.0, 1.1 Hz, 1 
H, C8-Heq), 2.31 – 2.21 (comp, 2 H, C11-Heq and C11-Hax), 2.19 – 2.10 (m, 1 H, C8-Hax), 
1.76 (s, 1 H, N13-H). 13C NMR (101 MHz, CDCl3) δ 159.9 (d, J = 250.6 Hz, C2), 145.7 
(C10), 130.4 (d, J = 13.4 Hz, C3), 128.9 (d, J = 5.6 Hz, C4), 127.6 (d, J = 3.5 Hz, C5), 
120.7 (d, J = 9.9 Hz, C6), 118.9 (d, J = 25.7 Hz, C1), 108.9 (C9), 55.4 (d, J = 2.0 Hz, 
C7), 48.0 (C12), 42.2 (C8), 34.9 (C11). 
 
 
 
 
2-(3,5-Dichlorophenyl)-4-methylenepiperidine (2.75f). Prepared in accord with 
the representative procedure to yield 82 mg (53%) of the title compound as a yellow oil. 
The crude product was purified by flash column chromatography, eluting with 
hexanes/ethyl acetate (1:1); 1H NMR (400 MHz, CDCl3) δ 7.31 – 7.26 (dd, J = 2.0, 0.5 
Hz, 2 H), 7.23 (t, J = 1.9 Hz, 1 H), 4.74 (comp, 2 H), 3.53 (dd, J = 11.3, 2.9 Hz, 1 H), 
3.30 – 3.20 (m, 1 H), 2.76 – 2.67 (m, 1 H), 2.37 (dd, J = 13.0, 3.0, 1.0 Hz, 1 H), 2.29 – 
2.20 (comp, 2 H), 2.17 – 2.07 (m, 1 H), 1.79 (s, 1 H). 13C NMR (101 MHz, CDCl3) δ 
147.9, 145.6, 134.9, 127.4, 125.2, 109.0, 62.1, 47.8, 43.8, 34.7. HRMS (ESI) m/z calcd 
for C12 H13Cl2N (M+H)+, 242.0498; found, 242.0504 
NMR assignments. For 2.75f: 1H NMR (400 MHz, CDCl3) δ 7.31 – 7.26 (dd, J = 
2.0, 0.5 Hz, 2 H, C6-H and C2-H), 7.23 (t, J = 1.9 Hz, 1 H, C4-H), 4.74 (comp, 2 H, C10-
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H2), 3.53 (dd, J = 11.3, 2.9 Hz, 1 H, C7-H), 3.30 – 3.20 (m, 1 H, C12-Heq), 2.76 – 2.67 
(m, 1 H, C12-Hax), 2.37 (dd, J = 13.0, 3.0, 1.0 Hz, 1 H, C8-Heq), 2.29 – 2.20 (comp, 2 H, 
C11-Heq and C11-Hax), 2.17 – 2.07 (m, 1 H, C8-Hax), 1.79 (s, 1 H, N13-H). 13C NMR (101 
MHz, CDCl3) δ 147.9, (C3 and C5) 145.6 (C1), 134.9 (C4), 127.4 (C6 and C2), 125.2 
(C10), 109.0 (C9), 62.1 (C7), 47.8 (C12), 43.8 (C8), 34.7 (C11). 
 
 
2-(Benzo[1,3]dioxol-5-yl)-4-methylenepiperidine (2.75g). Prepared in accord 
with the representative procedure to yield 60 mg (43%) of the title compound as an 
amber oil. The crude product was purified by flash column chromatography, eluting with 
hexanes/ethyl acetate (1:1); 1H NMR (400 MHz, CDCl3) δ 6.90 (d, J = 1.7 Hz, 1 H), 6.81 
(dd, J = 7.9, 1.5 Hz, 1 H), 6.73 (d, J = 8.0 Hz, 1 H), 5.91 (s, 2 H), 4.71 (d, J = 10.0 Hz, 2 
H), 3.48 (dd, J = 11.3, 2.9 Hz, 1 H), 3.28 – 3.20 (m, 1 H), 2.77 – 2.64 (m, 1 H), 2.34 (dd, 
J = 13.2, 3.1 Hz, 1 H), 2.27 – 2.15 (m, 3 H), 1.88 (br s, 1 H). 13C NMR (101 MHz, 
CDCl3) δ 147.6, 146.6, 146.6, 138.6, 119.7, 108.3, 108.1, 107.1, 100.9, 62.9, 48.0, 44.0, 
34.9. HRMS (ESI) m/z calcd for C13 H15NO2 (M+H)+,218.1176; found, 218.1182. 
NMR assignments. For 2.75g: 1H NMR (400 MHz, CDCl3) δ 6.90 (d, J = 1.7 Hz, 
1 H, C6-H), 6.81 (dd, J = 7.9, 1.5 Hz, 1 H, C2-H), 6.73 (d, J = 8.0 Hz, 1 H, C3-H), 5.91 
(s, 2 H, C7-H2), 4.71 (d, J = 10.0 Hz, 2 H, C11-H2), 3.48 (dd, J = 11.3, 2.9 Hz, 1 H, C8-
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H), 3.28 – 3.20 (m, 1 H, C13-Heq), 2.77 – 2.64 (m, 1 H, C13-Hax), 2.34 (dd, J = 13.2, 3.1 
Hz, 1 H, C9-Heq), 2.27 – 2.15 (comp, 3 H, C9-Hax and C12-Heq and C12-Hax), 1.88 (br s, 1 
H, N14-H). 13C NMR (101 MHz, CDCl3) δ 147.6 (C4), 146.60 (C5), 146.57 (C1), 138.6 
(C2), 119.7 (C3), 108.3 (C6), 108.1 (C11), 107.1 (C10), 100.9 (C7), 62.9 (C8), 48.0 
(C13), 44.0 (C9), 34.9 (C12). 
 
 
4-Methylene-2-(thiophen-3-yl)piperidine (2.75h). Prepared in accord with the 
representative procedure to yield 79 mg (69%) of the title compound as a clear oil. The 
crude product was purified by flash column chromatography, eluting with hexanes/ethyl 
acetate (1:1); 1H NMR (400 MHz, CDCl3) δ 7.26 (dd, J = 5.0, 3.0 Hz, 1 H), 7.19 – 7.14 
(m, 1 H), 7.09 (dd, J = 5.0, 1.3 Hz, 1 H), 4.77 – 4.68 (comp, 2 H), 3.71 (dd, J = 11.1, 3.0 
Hz, 1 H), 3.23 (ddd, J = 11.5, 4.7, 2.7 Hz, 1 H), 2.73 (td, J = 11.3, 4.5 Hz, 1 H), 2.49 
(ddd, J = 13.1, 3.1, 1.2 Hz, 1 H), 2.30 – 2.16 (comp, 3 H), 1.81 (s, 1 H). 13C NMR (101 
MHz, CDCl3) δ 146.3, 145.7, 126.3, 125.7, 120.2, 108.5, 58.4, 47.8, 43.3, 35.2. HRMS 
(ESI) m/z calcd for C13 H15NO2 (M+H)+,180.0841; found, 180.0850. 
 NMR assignments. For 2.75h: 1H NMR (400 MHz, CDCl3) δ 7.26 (dd, J = 5.0, 
3.0 Hz, 1 H, C3-H), 7.19 – 7.14 (m, 1 H, C2-H), 7.09 (dd, J = 5.0, 1.3 Hz, 1 H, C4-H), 
4.77 – 4.68 (comp, 2 H, C8-H2), 3.71 (dd, J = 11.1, 3.0 Hz, 1 H, C5-H), 3.23 (ddd, J = 
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11.5, 4.7, 2.7 Hz, 1 H, C10-Heq), 2.73 (td, J = 11.3, 4.5 Hz, 1 H, C10-Hax), 2.49 (ddd, J = 
13.1, 3.1, 1.2 Hz, 1 H, C6-Heq), 2.30 – 2.16 (comp, 3 H, C6-Hax and C9-Heq and C9-Hax), 
1.81 (s, 1 H, N11-H). 13C NMR (101 MHz, CDCl3) δ 146.3 (C1), 145.7 (C4), 126.3 (C3), 
125.7 (C2), 120.2 (C8), 108.5 (C7), 58.4 (C5), 47.8 (C10), 43.3 (C6), 35.2 (C9). 
Representative procedure for the methylation of 2-arylpiperidines: 
 
2-(2-Bromophenyl)-1-methyl-4-methylenepiperidine (2.78a).  A solution of 
2.75a  (100 mg, 0.4 mmol) in acetonitrile (5 mL) was cooled to 0 °C, and formaldehyde 
(200 μL, 2.4 mmol, 37% aq. soln.) and NaBH3CN (50 mg, 0.8 mmol) were added 
sequentially. This suspension stirred for 2 h at room temperature before adding acetic 
acid (3 mL). The resulting solution stirred for 0.5 h open to air before being transferred to 
a separatory funnel with diethyl ether (30 mL) and 1 M HCl (15 mL). The layers were 
separated and the organic layer was washed with 1M HCl (3 x 15 mL). The combined 
aqueous layers were basified with 10 M NaOH until the pH was greater than 12 by pH 
paper. This aqueous solution was then washed with dichloromethane (3 x 30 mL) and the 
combined organic layers were dried (MgSO4) and concentrated under reduced pressure to 
give 94 mg (88%) of compound 2.78a as a yellow solid. 1H NMR (400 MHz,CDCl3) δ 
7.57 (dd, J = 7.8, 1.8 Hz, 1 H), 7.52 (dd, J = 8.0, 1.2 Hz, 1 H), 7.32 (dddd, J = 7.8, 7.3, 
1.3, 0.5 Hz, 1 H), 7.09 (ddd, J = 8.0, 7.2, 1.8 Hz, 1 H), 4.76 – 4.67 (comp, 2 H), 3.46 (dd, 
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J = 11.4, 3.2 Hz, 1 H), 3.12 (ddd, J = 11.0, 4.9, 2.2 Hz, 1 H), 2.51 – 2.40 (m, 1 H), 2.40 – 
2.19 (comp, 3 H), 2.18 – 2.09 (m, 1 H), 2.04 (s, 3 H). 13C NMR (101 MHz, CDCl3) δ 
145.5, 142.5, 132.7(, 128.9, 128.2, 127.8, 123.6, 108.1, 68.8, 57.8, 43.4, 42.6, 34.7. 
HRMS (ESI) m/z calcd for C13 H16BrN (M+H)+, 266.0539; found, 266.0548 
NMR assignments. For 2.78a: 1H NMR (400 MHz,CDCl3) δ 7.57 (dd, J = 7.8, 
1.8 Hz, 1 H, C3-H), 7.52 (dd, J = 8.0, 1.2 Hz, 1 H, C6-H), 7.32 (dddd, J = 7.8, 7.3, 1.3, 
0.5 Hz, 1 H, C4-H), 7.09 (ddd, J = 8.0, 7.2, 1.8 Hz, 1 H, C5-H), 4.76 – 4.67 (comp, 2 H, 
C10-H), 3.46 (dd, J = 11.4, 3.2 Hz, 1 H, C7-H), 3.12 (ddd, J = 11.0, 4.9, 2.2 Hz, 1 H, 
C12-Heq), 2.51 – 2.40 (m, 1 H, C12-Hax), 2.40 – 2.19 (comp, 3 H, C11-Heq and C11-Hax 
and C8-Heq), 2.18 – 2.09 (m, 1 H, C8-Hax), 2.04 (s, 3 H, C13-H3). 13C NMR (101 MHz, 
CDCl3) δ 145.5 (C2), 142.5 (C1), 132.7 (C6), 128.9 (C5), 128.2 (C4), 127.8 (C3), 123.6 
(C10), 108.1 (C9), 68.8 (C7), 57.8 (C14), 43.4 (C15), 42.6 (C10), 34.7 (C13). 
 
 
 
 2-(2,3-Dimethoxyphenyl)-1-methyl-4-methylenepiperidine (2.78b). Prepared in 
accord with the representative procedure to yield 14 mg (66%) of the title compound as 
an off white solid.  1H NMR (400 MHz, CDCl3) δ 7.11 – 7.04 (comp, 2 H), 6.80 (dd, J = 
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6.7, 2.9 Hz, 1 H), 4.71 (dq, J = 15.6, 1.9 Hz, 2 H), 3.86 (s, 3 H), 3.80 (s, 3 H), 3.44 (dd, J 
= 10.3, 4.3 Hz, 1 H), 3.14 (ddd, J = 11.0, 4.8, 2.2 Hz, 1 H), 2.55 – 2.40 (m, 1 H), 2.33 – 
2.18 (comp, 4 H), 2.05 (s, 3 H). 13C NMR (101 MHz, CDCl3) δ 152.6, 146.7, 146.1, 
137.3, 124.4, 119.5, 110.4, 107.8, 62.9, 60.8, 58.0, 55.6, 43.6, 43.3, 34.7. HRMS (ESI) 
m/z calcd for C15H21NO2 (M+H)+, 248.1645; found, 248.1652 
NMR assignments. For 2.78b: 1H NMR (400 MHz, CDCl3) δ 7.11 – 7.04 (comp, 
2 H, C6-H and C5-H), 6.80 (dd, J = 6.7, 2.9 Hz, 1 H, C4-H), 4.71 (dq, J = 15.6, 1.9 Hz, 2 
H, C12-H), 3.86 (s, 3 H, C7-H or C8-H), 3.80 (s, 3 H, C7-H or C8-H), 3.44 (dd, J = 10.3, 
4.3 Hz, 1 H, C9-H), 3.14 (ddd, J = 11.0, 4.8, 2.2 Hz, 1 H, C14-Heq), 2.55 – 2.40 (m, 1 H, 
C14-Hax), 2.33 – 2.18 (comp, 4 H, C10-H2 and C13-H2), 2.05 (s, 3 H, C15-H3). 13C NMR 
(101 MHz, CDCl3) δ 152.6 (C1), 146.7 (C2 or C3), 146.1 (C2 or C3), 137.3 (C5 or C6), 
124.4 (C5 or C6), 119.5 (C4), 110.4 (C12), 107.8 (C11), 62.9 (C9), 60.8 (C7 or C8), 58.0 
(C7 or C8), 55.6 (C15), 43.6 (C14), 43.3 (C10), 34.7 (C13). 
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 2-(3,4-Dimethoxyphenyl)-1-methyl-4-methylenepiperidine (2.78c). Prepared in 
accord with the representative procedure to yield 20 mg (94%) of the title compound as a 
yellow solid. 1H NMR (400 MHz, CDCl3) δ 6.90 (d, J = 1.7 Hz, 1 H), 6.85 – 6.78 (comp, 
2 H), 4.74 – 4.63 (comp, 2 H), 3.90 (s, 3 H), 3.87 (s, 3 H), 3.15 – 3.04 (m, 1 H), 2.75 (dd, 
J = 11.1, 3.4 Hz, 1 H), 2.53 – 2.40 (m, 1 H), 2.40 – 2.24 (comp, 3 H), 2.13 (ddd, J = 12.8, 
11.1, 2.9 Hz, 1 H), 2.02 (s, 3 H). 13C NMR (126 MHz, CDCl3) δ 149.1, 148.1, 146.0, 
136.3, 119.7, 110.8, 109.9, 107.9, 71.4, 57.9, 55.9, 55.9, 44.0, 43.7, 34.6. HRMS (ESI) 
m/z calcd for C15H21NO2 (M+H)+, 248.1645; found, 248.1652 
NMR assignements. For 2.78c: 1H NMR (400 MHz, CDCl3) δ 6.90 (d, J = 1.7 
Hz, 1 H, C2-H), 6.85 – 6.78 (comp, 2 H, C5-H and C6-H), 4.74 – 4.63 (comp, 2 H, C12-
H), 3.90 (s, 3 H, C7-H3 or C8-H3), 3.87 (s, 3 H, C7-H3 or C8-H3), 3.15 – 3.04 (m, 1 H, 
C9-H), 2.75 (dd, J = 11.1, 3.4 Hz, 1 H, C14-Heq), 2.53 – 2.40 (m, 1 H, C14-Hax), 2.40 – 
2.24 (comp, 3 H, C10-Heq and C13-Heq and C13-Hax), 2.13 (ddd, J = 12.8, 11.1, 2.9 Hz, 1 
H, C10-Hax), 2.02 (s, 3 H, C15-H3). 13C NMR (126 MHz, CDCl3) δ 149.1 (C1), 148.1 (C3 
or C4), 146.0 (C3 or C4), 136.3 (C6), 119.7 (C4 or C5), 110.8 (C4 or C5), 109.9 (C12), 
107.9 (C11), 71.4 (C9), 57.9 (C7 or C8), 55.9 (C7 or C8), 55.9 (C15), 44.0 (C14), 43.7 
(C10), 34.6 (C13).  
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 2-(2,5-Dimethoxyphenyl)-1-methyl-4-methylenepiperidine (2.78d). Prepared in 
accord with the representative procedure to yield 20 mg (94%) of the title compound as a 
clear oil. 1H NMR (400 MHz, CDCl3) δ 7.11 (br s, 1 H), 6.81 (d, J = 8.9 Hz, 1 H), 6.75 
(dd, J = 8.9, 3.0 Hz, 1 H), 4.77 – 4.64 (comp, 2 H), 3.79 (s, 3 H), 3.78 (s, 3 H), 3.56 – 
3.40 (m, 1 H), 3.14 (d, J = 11.1 Hz, 1 H), 2.61 – 2.41 (m, 1 H), 2.37 – 2.17 (comp, 4 H), 
2.08 (s, 3 H). 13C NMR (101 MHz, CDCl3) δ 154.2, 151.2, 146.2, 132.9, 113.0, 112.9, 
112.3, 107.7, 62.6, 58.0, 56.3, 55.8, 43.3, 42.6, 34.7. HRMS (ESI) m/z calcd for 
C15H21NO2 (M+H)+, 248.1645; found, 248.1651 
 NMR assignements. For 2.78d: 1H NMR (400 MHz, CDCl3) δ 7.11 (br s, 1 H, 
C6-H), 6.81 (d, J = 8.9 Hz, 1 H, C3-H), 6.75 (dd, J = 8.9, 3.0 Hz, 1 H, C4-H), 4.77 – 4.64 
(comp, 2 H, C12-H), 3.79 (s, 3 H, C7-H3 or C8-H3), 3.78 (s, 3 H, C7-H3 or C8-H3), 3.56 – 
3.40 (m, 1 H, C9-H), 3.14 (d, J = 11.1 Hz, 1 H, C14-Heq), 2.61 – 2.41 (m, 1 H, C14-Hax), 
2.37 – 2.17 (comp, 4 H, C10-H2, and C13-H2), 2.08 (s, 3 H, C15-H3). 13C NMR (101 
MHz, CDCl3) δ 154.2 (C2 or C5), 151.2 (C2 or C5), 146.2 (C1), 132.9 (C3 or C4), 113.0 
(C3 or C4), 112.9 (C6), 112.3 (C12), 107.7 (C11), 62.6 (C9), 58.0 (C15), 56.3 (C7 or 
C8), 55.8 (C7 or C8), 43.3 (C14), 42.6 (C10), 34.7 (C13).  
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 2-(4-Bromo-2-fluorophenyl)-1-methyl-4-methylenepiperidine (2.78e). 
Prepared in accord with the representative procedure to yield 16 mg (74%) of the title 
compound as an amber oil. 1H NMR (400 MHz, CDCl3) δ 7.40 (t, J = 7.9 Hz, 1 H), 7.29 
(dd, J = 8.4, 2.0 Hz, 1 H), 7.21 (dd, J = 9.6, 1.9 Hz, 1 H), 4.72 (dt, J = 13.9, 1.9 Hz, 2 H), 
3.25 (t, J = 7.3 Hz, 1 H), 3.09 (ddd, J = 11.2, 4.9, 2.3 Hz, 1 H), 2.44 (td, J = 12.7, 4.6 Hz, 
1 H), 2.32 – 2.24 (comp, 3 H), 2.17 (ddd, J = 12.8, 11.1, 3.0 Hz, 1 H), 2.03 (s, 3 H). 13C 
NMR (101 MHz, CDCl3) δ 160.2 (d, J = 250.3 Hz), 145.1, 129.9 (d, J = 5.1 Hz), 129.7 
(d, J = 12.7 Hz), 127.8 (d, J = 3.7 Hz), 120.5 (d, J = 9.8 Hz), 119.0 (d, J = 26.1 Hz), 
108.4, 62.2, 57.7, 43.5, 42.42, 34.6. HRMS (ESI) m/z calcd for C13 H15BrFN (M+H)+, 
284.0445; found, 284.0452 
 NMR assignements. For 2.78e: 1H NMR (400 MHz, CDCl3) δ 7.40 (t, J = 7.9 
Hz, 1 H, C6-H), 7.29 (dd, J = 8.4, 2.0 Hz, 1 H, C5-H), 7.21 (dd, J = 9.6, 1.9 Hz, 1 H, C3-
H), 4.72 (dt, J = 13.9, 1.9 Hz, 2 H, C10-H2), 3.25 (t, J = 7.3 Hz, 1 H, C7-H), 3.09 (ddd, J 
= 11.2, 4.9, 2.3 Hz, 1 H, C12-Heq), 2.44 (td, J = 12.7, 4.6 Hz, 1 H, C-12-Hax), 2.32 – 2.24 
(comp, 3 H, C8-Heq and C11-Heq and C11-Hax), 2.17 (ddd, J = 12.8, 11.1, 3.0 Hz, 1 H, 
C8-Hax), 2.03 (s, 3 H, C13-H3). 13C NMR (101 MHz, CDCl3) δ 160.2 (d, J = 250.3 Hz, 
C2), 145.1 (C10), 129.9 (d, J = 5.1 Hz, C4), 129.7 (d, J = 12.7 Hz, C1), 127.8 (d, J = 3.7 
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Hz, C5), 120.5 (d, J = 9.8 Hz, C6), 119.0 (d, J = 26.1 Hz, C3), 108.4 (C9), 62.2, (C7), 
57.7 (C13), 43.5 (C12), 42.42 (C8), 34.6 (C11). 
 
 
 
 
 2-(3,5-Dichlorophenyl)-1-methyl-4-methylenepiperidine (2.78f). Prepared in 
accord with the representative procedure to yield 12 mg (56%) of the title compound as 
an amber oil. 1H NMR (400 MHz, CDCl3) δ 7.24 (s, 3 H), 4.71 (dq, J = 18.8, 1.8 Hz, 2 
H), 3.08 (ddd, J = 11.1, 5.0, 2.3 Hz, 1 H), 2.77 (dd, J = 10.4, 4.1 Hz, 1 H), 2.44 (td, J = 
12.9, 4.7 Hz, 1 H), 2.31 – 2.20 (comp, 3 H), 2.13 (ddd, J = 12.7, 11.1, 2.9 Hz, 1 H), 2.02 
(s, 3 H). 13C NMR (101 MHz, CDCl3) δ 147.7, 145.1, 135.0, 127.3, 125.9, 108.4, 70.6, 
57.6, 44.0, 43.9, 34.9. HRMS (ESI) m/z calcd for C13 H15Cl2N (M+H)+, 256.0654; found, 
256.0661 
 NMR assignements. For 2.78f: 1H NMR (400 MHz, CDCl3) δ 7.24 (s, 3 H, C6-H 
and C2-H and C4-H), 4.71 (dq, J = 18.8, 1.8 Hz, 2 H, C10-H2), 3.08 (ddd, J = 11.1, 5.0, 
2.3 Hz, 1 H, C7-H), 2.77 (dd, J = 10.4, 4.1 Hz, 1 H, C12-Heq), 2.44 (td, J = 12.9, 4.7 Hz, 
1 H, C12-Hax), 2.31 – 2.20 (comp, 3 H, C8-Heq and C11-Heq and C11-Hax), 2.13 (ddd, J = 
12.7, 11.1, 2.9 Hz, 1 H, C8-Hax), 2.02 (s, 3 H, C13-H3). 13C NMR (101 MHz, CDCl3) δ 
Cl
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147.7 (C1), 145.1 (C3 and C5), 135.0 (C6 and C2), 127.3 (C4), 125.9 (C10), 108.4 (C9), 
70.6 (C7), 57.6 (C13), 44.0 (C12), 43.9 (C8), 34.9 (C11). 
 
 2-(Benzo[d][1,3]dioxol-5-yl)-1-methyl-4-methylenepiperidine (2.78g). Prepared 
in accord with the representative procedure to yield 20 mg (94%) of the title compound 
as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 6.90 – 6.82 (m, 1 H), 6.79 – 6.70 (comp, 2 
H), 5.94 (dd, J = 4.7, 1.5 Hz, 2 H), 4.68 (dq, J = 16.6, 1.9 Hz, 2 H), 3.08 (ddd, J = 11.1, 
5.0, 2.3 Hz, 1 H), 2.72 (dd, J = 9.8, 4.7 Hz, 1 H), 2.52 – 2.37 (m, 1 H), 2.34 – 2.22 
(comp, 3 H), 2.11 (ddd, J = 12.7, 11.1, 3.0 Hz, 1 H), 2.01 (s, 3 H). 13C NMR (101 MHz, 
CDCl3) δ 147.8, 146.6, 146.1, 138.0, 120.6, 108.0, 107.8, 107.5, 100.9, 71.2, 57.8, 44.1, 
43.7, 34.7. HRMS (ESI) m/z calcd for C14H17NO2 (M+H)+, 232.1332; found, 232.1336 
 NMR assignements. For 2.78g: 1H NMR (400 MHz, CDCl3) δ 6.90 – 6.82 (m, 1 
H, C6-H), 6.79 – 6.70 (comp, 2 H, C3-H and C2-H), 5.94 (dd, J = 4.7, 1.5 Hz, 2 H, C7-
H2), 4.68 (dq, J = 16.6, 1.9 Hz, 2 H, C11-H2), 3.08 (ddd, J = 11.1, 5.0, 2.3 Hz, 1 H, C8-
H), 2.72 (dd, J = 9.8, 4.7 Hz, 1 H, C13-Heq), 2.52 – 2.37 (m, 1 H, C13-Hax), 2.34 – 2.22 
(comp, 3 H, C9-Heq and C12-Heq and C12-Hax), 2.11 (ddd, J = 12.7, 11.1, 3.0 Hz, 1 H, C9-
Hax), 2.01 (s, 3 H, C14-H3).  13C NMR (101 MHz, CDCl3) δ 147.8 (C4), 146.6 (C5), 146.1 
(C1), 138.0 (C2), 120.6 (C3), 108.0 (C6), 107.8 (C11), 107.5 (C10), 100.9 (C7), 71.2 
(C8), 57.8 (C14), 44.1 (C13), 43.7 (C9), 34.7 (C12). 
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 1-Methyl-4-methylene-2-(thiophen-3-yl)piperidine (2.78h). Prepared in accord 
with the representative procedure to yield 20 mg (92%) of the title compound as a clear 
oil. 1H NMR (400 MHz, CDCl3) δ 7.30-7.25 (m, 1 H), 7.14 – 7.08 (comp, 2 H), 4.70 (dq, 
J = 15.9, 1.9 Hz, 2 H), 3.11 – 2.98 (comp, 2 H), 2.54 – 2.36 (comp, 2 H), 2.36 – 2.23 
(comp, 2 H), 2.14 (ddd, J = 12.4, 11.2, 3.1 Hz, 1 H), 2.04 (s, 3 H). 13C NMR (101 MHz, 
CDCl3) δ 145.8, 144.8, 126.6, 125.7, 121.4, 108.0, 66.3, 57.6, 43.7, 43.1, 34.6. HRMS 
(ESI) m/z calcd for C11H15NS (M+H)+, 194.0998; found, 194.1001 
 NMR assignements. For 2.78h: 1H NMR (400 MHz, CDCl3) δ 7.3-7.25 (comp, 1 
H, C1-H), 7.14 – 7.08 (comp, 2 H, C3-H and C4-H), 4.70 (dq, J = 15.9, 1.9 Hz, 2 H, C8-
H2), 3.11 – 2.98 (comp, 2 H, C5-H and C10-Heq), 2.54 – 2.36 (comp, 2 H, C10-Hax and 
C6-Heq), 2.36 – 2.23 (comp, 2 H, C9-Heq and C9-Hax), 2.14 (ddd, J = 12.4, 11.2, 3.1 Hz, 1 
H, C6-Hax), 2.04 (s, 3 H, C11-H3). 13C NMR (101 MHz, CDCl3) δ 145.8 (C2), 144.8 (C1), 
126.6 (C3 or C4), 125.7 (C3 or C4), 121.4 (C8), 108.0 (C7), 66.3 (C5), 57.6 (C11), 43.7 
(C10), 43.1 (C6), 34.6 (C9).  
 
Representative procedure for the acylation of 2-arylpiperidines: 
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 1-(2-(2-Bromophenyl)-4-methylenepiperidin-1-yl)ethan-1-one (2.79a). A 
solution of compound 2.75a (100 mg, 0.4 mmol) and triethylamine (121 mg, 167 μL, 1.2 
mmol) in dichloromethane (5 mL) was cooled to 0 °C, and acetyl chloride (63 mg, 57 μL, 
0.8 mmol) was added via syringe. The reaction was allowed to stir overnight at room 
temperature before adding 1 M HCl (5 mL) and stirring an additional 15 min. This 
biphasic mixture was then transferred to a separatory funnel with dichloromethane and 1 
M HCl. The layers were separated and the aqueous layer was washed with 
dichloromethane (3 x 15 mL). The combined organic extracts were dried (MgSO4) and 
the solvent was removed under reduced pressure. The crude product was purified via 
column chromatography eluting with hexanes/ethyl acetate (4:1) to give 20 mg (85%) of 
compound 2.79z as a yellow oil. 1H NMR (500 MHz, Toluene-d8, 100 °C) δ 7.39 – 7.27 
(m, 1 H), 7.22 – 7.13 (m, 1 H), 6.96 – 6.90 (m, 1 H), 6.78 – 6.68 (m, 1 H), 5.39 (br s, 1 
H), 4.68 (d, J = 7.2 Hz, 2 H), 4.12 (br s, 1 H), 3.23 – 3.05 (m, 1 H), 2.65 (dd, J = 14.5, 6.5 
Hz, 1 H), 2.35 (dd, J = 14.4, 6.0 Hz, 1 H), 2.26 – 2.06 (comp, 2 H), 1.72 (s, 3 H). 1H 
NMR (500 MHz, Toluene-d8, 27 °C) δ 7.38-6.98 (rotamers, comp, 2 H), 6.95-6.81 (m, 1 
H), 6.72-6.61 (m, 1 H), 6.19-5.65 and 5.34-4.86 (rotamers, br s, 1 H), 4.77-4.36 
(rotamers, comp 3 H), 3.27-2.71 (rotamers, br s, 1 H), 2.56 (dd, J = 14.26, 6.64 Hz, 1 H), 
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2.40-1.83 (rotamers, comp, 3 H), 1.79-1.55 (br s, 3 H). 13C NMR (101 MHz, CDCl3) 
(rotamers) δ 171.5, 141.6, 140.8, 133.3, 129.0, 128.6, 128.1, 127.0, 121.7, 112.0, 59.0, 
53.4, 42.9, 39.0, 37.9, 36.3, 33.3, 31.0, 21.8. HRMS (ESI) m/z calcd for C14H16BrNO 
(M+Na)+, 316.0307; found, 316.0317 
 NMR assignments. For compound 2.79a: 1H NMR (500 MHz, Toluene-d8, 100 
°C) δ 7.39 – 7.27 (m, 1 H, C3-H), 7.22 – 7.13 (m, 1 H, C6-H), 6.96 – 6.90 (m, 1 H, C5-
H), 6.78 – 6.68 (m, 1 H, C4-H), 5.39 (br s, 1 H, C7-H), 4.68 (d, J = 7.2 Hz, 2 H, C10-H2), 
4.12 (br s, 1 H, C12-Heq), 3.23 – 3.05 (m, 1 H, C12-Hax), 2.65 (dd, J = 14.5, 6.5 Hz, 1 H, 
C8-Heq), 2.35 (dd, J = 14.4, 6.0 Hz, 1 H, C8-Hax), 2.26 – 2.06 (comp, 2 H, C11-Heq and 
C11-Hax), 1.72 (s, 3 H, C14-H3). 
 
 
 
 
1-(2-(2,3-Dimethoxyphenyl)-4-methylenepiperidin-1-yl)ethan-1-one (2.79b). 
Prepared in accord with the representative procedure to yield 16 mg (68%) of the title 
compound as a clear oil. The crude product was purified by flash column 
chromatography, eluting with hexanes/ethyl acetate (4:1). 1H NMR (400 MHz, CDCl3) δ 
N
OMe
1
23
4
5
6
7
8
9
10
11
12
13
14
2.79b
OMe
16
15
O
 76 
7.06-6.93 (comp, 2 H), 6.90-6.79 (comp, 2 H), 6.07-5.90 and 5.34-5.18 (rotamers, comp, 
1 H), 4.95-4.80 (comp, 2 H), 4.62-4.45 and 3.77-3.62 (rotamers, comp, 1 H), 3.93-3.80 
(comp, 6 H), 3.42-3.25 and 3.08-2.90 (rotamers, comp, 1 H), 2.80-2.62 (comp, 2 H), 
2.46-2.32 (comp, 2 H), 2.20-2.07 (rotamers, comp, 3 H). 13C NMR (101 MHz, CDCl3) 
(rotamers) δ 171.5, 169.6, 142.2, 141.6, 141.3, 140.8, 133.3, 129.0, 128.5, 128.1, 127.0, 
123.8, 123.4, 121.7, 119.2, 112.0, 111.8, 111.6, 59.0, 53.5, 42.9, 38.9, 37.8, 36.3, 33.3, 
31.0, 21.8. HRMS (ESI) m/z calcd for C16H21NO3 (M+H)+, 276.1594; found, 276.1599 
 
 
 
 
1-(2-(3,4-Dimethoxyphenyl)-4-methylenepiperidin-1-yl)ethan-1-one (2.79c). 
Prepared in accord with the representative procedure to yield 18 mg (76%) of the title 
compound as a clear oil. The crude product was purified by flash column 
chromatography, eluting with hexanes/ethyl acetate (1:1). 1H NMR (400 MHz, CDCl3) δ 
7.02-6.67 (rotamers, comp, 3 H), 6.13-5.96 and 5.17-5.03 (rotamers, comp, 1 H), 5.00-
4.79 (rotamers, comp, 2 H), 4.67-4.50 and 3.69-3.57 (rotamers, comp, 1 H), 3.91-3.75 
(rotamers, comp, 6 H), 3.11-2.95 and 2.78-2.51 (rotamers, comp, 1 H), 2.93-2.81 (m, 1 
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H), 2.78-2.51 (rotamers, comp, 1 H), 2.39-2.22 (comp, 2 H), 2.21-2.15 (comp, 3 H). 
HRMS (ESI) m/z calcd for C16H21NO3 (M+H)+, 276.1594; found, 276.1599 
 
 
 
 
 
1-(2-(2,5-Dimethoxyphenyl)-4-methylenepiperidin-1-yl)ethan-1-one (2.79d). 
Prepared in accord with the representative procedure to yield 18 mg (76%) of the title 
compound as an off white solid. The crude product was purified by flash column 
chromatography, eluting with hexanes/ethyl acetate (4:1); 1H NMR (400 MHz, CDCl3) δ 
7.10-6.91 (rotamers, comp, 1 H), 6.85-6.68 (comp, 2 H), 6.05-5.89 and 5.34-5.22 
(rotamers, comp, 1 H), 4.95-4.85 (comp, 2 H), 4.58-4.44 and 3.84-3.64 (rotamers, comp, 
1 H), 3.84-3.64 (rotamers, comp, 6 H), 3.44-3.25 and 3.03-2.86 (rotamers, comp, 1 H), 
2.78-2.61 (comp, 2 H), 2.46-2.31 (comp, 2 H), 2.17-2.07 (comp, 3 H). 13C NMR (101 
MHz, CDCl3) (rotamers) δ 170.6, 153.3, 150.8, 142.7, 130.6, 114.5, 112.3, 111.4, 111.2, 
55.6, 53.4, 52.7, 37.9, 37.6, 32.7, 29.7, 21.5. HRMS (ESI) m/z calcd for C16H21NO3 
(M+Na)+, 298.1414; found, 298.1421 
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1-(2-(4-Bromo-2-fluorophenyl)-4-methylenepiperidin-1-yl)ethan-1-one 
(2.79e). Prepared in accord with the representative procedure to yield 15 mg (64%) of the 
title compound as an off white solid. The crude product was purified by flash column 
chromatography, eluting with hexanes/ethyl acetate (10:1). 1H NMR (400 MHz, 
Chloroform-d) δ 7.32-7.14 (comp, 3 H), 6.08-5.92 and 5.33-5.16 (rotamers, br s, 1 H), 
4.97-4.83 (comp, 2 H), 4.63-4.46 and 3.77-3.66 (rotamers, comp, 1 H), 3.30-3.10 and 
2.95-2.81 (rotamers, comp, 1 H), 2.81-2.58 (comp, 2 H), 2.43-2.29 (comp, 2 H), 2.22-
2.04 (rotamers, comp, 3 H). HRMS (ESI) m/z calcd for C14H15BrFNO (M+H)+, 
312.0394; found, 312.0400 
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 1-(2-(3,5-Dichlorophenyl)-4-methylenepiperidin-1-yl)ethan-1-one (2.79f). 
Prepared in accord with the representative procedure to yield 19 mg (79%) of the title 
compound as an off white solid. The crude product was purified by flash column 
chromatography, eluting with hexanes/ethyl acetate (10:1). 1H NMR (400 MHz, CDCl3) 
δ 7.30-7.06 (comp, 3 H), 6.06-5.95 and 5.11-5.01 (rotamers, comp, 1 H), 5.00-4.82 
(comp, 2 H), 4.68-4.55 and 3.77-3.64 (rotamers, 1 H), 3.08-2.92 and 2.74-2.65 (rotamers, 
comp, 1 H) 2.89-2.77 (m, 1 H), 2.74-2.54 (m, 1 H), 2.35-2.11 (comp, 5 H).  13C NMR 
(101 MHz, CDCl3) (rotamers) δ 169.6, 143.7, 140.7, 135.6, 135.0, 127.5, 127.2, 126.2, 
125.1, 112.8, 50.1, 42.7, 38.2, 37.6, 35.5, 34.2, 32.8, 29.7, 21.8. HRMS (ESI) m/z calcd 
for C19H19BrFNO2S (M+Na)+, 446.0196; found, 446.0201 
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1-(2-(Benzo[d][1,3]dioxol-5-yl)-4-methylenepiperidin-1-yl)ethan-1-one 
(2.79g).  Prepared in accord with the representative procedure to yield 16 mg (69%) of 
the title compound as a clear oil. The crude product was purified by flash column 
chromatography, eluting with hexanes/ethyl acetate (4:1); 1H NMR (400 MHz, CDCl3) δ 
6.90-6.63 (comp, 3 H), 6.06-5.98 and 5.08-4.99 (rotamers, br s, 1 H), 5.96-5.85 (br s, 2 
H), 4.98-4.77 (comp, 2 H), 4.65-4.49 and 3.71-3.54 (rotamers, comp, 1 H), 3.11-2.92 and 
22.75-2.48 (rotamers, 1 H), 2.88-2.78 (m, 1 H), 2.75-2.48 (rotamers, comp, 1 H), 2.37-
2.22 (comp, 2 H), 2.18-2.14 (br s, 3 H). 13C NMR (101 MHz, CDCl3) (rotamers) δ 141.8, 
120.9, 112.1, 108.3, 107.9, 100.9, 50.3, 42.4, 37.9, 35.9, 34.4, 33.0, 29.7, 21.8. HRMS 
(ESI) m/z calcd for C15H17NO3 (M+H)+, 260.1281; found, 260.1286 
 
 
 
1-(4-Methylene-2-(thiophen-3-yl)piperidin-1-yl)ethan-1-one (2.79h). Prepared 
in accord with the representative procedure to yield 20 mg (82%) of the title compound 
as a clear oil. The crude product was purified by flash column chromatography, eluting 
with hexanes/ethyl acetate (4:1). 1H NMR (400 MHz, CDCl3) δ 7.37-7.16 and 7.14-7.06 
(rotamers, comp, 2 H), 7.03-6.88 (m, 1 H), 6.17-6.00 and 5.21-5.10 (rotamers, 1 H), 4.99-
4.81 (comp, 2 H), 4.63-4.53 and 3.69-3.57 (rotamers, comp, 1 H), 3.08-2.95 and 2.71-
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2.51 (rotamers, comp, 1 H), 2.90-2.75 (m, 1 H), 2.71-2.51 (rotamers, comp 1 H), 2.34-
2.09 (comp, 5 H). 13C NMR (101 MHz, CDCl3) (rotamers) δ 169.4, 169.0, 142.1, 141.5, 
141.3, 140.6, 127.7, 126.4, 125.4, 122.5, 122.1, 112.0, 54.4, 47.8, 42.5, 38.1, 38.0, 36.6, 
34.6, 33.5, 29.7, 21.8, 21.6. HRMS (ESI) m/z calcd for C12 H15NOS (M+Na)+, 244.0767; 
found, 244.0774 
 
 
Representative procedure for the tosylation of 2-arylpiperidines: 
 
2-(2-Bromophenyl)-4-methylene-1-tosylpiperidine (2.80a). A solution of 
compound 122 (100 mg, 0.4 mmol) and triethylamine (121 mg, 167 μL, 1.2 mmol) in 
dichloromethane (5 mL) was cooled to  0 °C, and toluenesulfonyl chloride (152 mg, 0.8 
mmol) was added. The reaction was allowed to stir overnight at room temperature before 
cooling the solution back to 0 °C and adding pyridine (500 μL) and distilled water (500 
μL) sequentially. The reaction stirred for an additional 30 minutes at room temperature 
before being transferred to a separatory funnel with dichloromethane (15 mL) and 1 M 
HCl (15 mL). The layers were separated and the aqueous layer was washed with 
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dichloromethane (3 x 20 mL). The combined organic layers were then washed with sat. 
aq. NaHCO3 (3 x 15 mL), dried (MgSO4), and concentrated under reduced pressure to 
yield 95 mg (94%) of compound 125 as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.57 
(dd, J = 8.3, 2.5 Hz, 2 H), 7.47 (dq, J = 7.9, 1.4 Hz, 1 H), 7.34 (dq, J = 7.8, 1.7 Hz, 1 H), 
7.21 – 7.08 (comp, 3 H), 7.04 (tdd, J = 7.7, 3.0, 1.7 Hz, 1 H), 5.34 (td, J = 6.0, 2.4 Hz, 1 
H), 4.76 – 4.62 (comp, 2 H), 3.76 (dtd, J = 13.2, 5.4, 2.5 Hz, 1 H), 3.70 – 3.57 (m, 1 H), 
2.64 (dd, J = 14.2, 6.3 Hz, 1H), 2.48 – 2.29 (comp, 6 H). 13C NMR (101 MHz, CDCl3) δ 
143.2, 140.9, 139.8, 136.3, 132.9, 129.4, 128.6, 128.5, 127.3, 127.1, 122.3, 112.1, 57.9, 
43.8, 38.3, 31.9, 21.5. HRMS (ESI) m/z calcd for C19H19BrFNO2S (M+H)+, 406.0471; 
found, 406.0475 
 NMR Assignments. For 2.80a: 1H NMR (400 MHz, CDCl3) δ 7.57 (dd, J = 8.3, 
2.5 Hz, 2 H, C14-H2), 7.47 (dq, J = 7.9, 1.4 Hz, 1 H, C3-H), 7.34 (dq, J = 7.8, 1.7 Hz, 1 
H, C6-H), 7.21 – 7.08 (comp, 3 H, C15-H2 and C5-H), 7.04 (tdd, J = 7.7, 3.0, 1.7 Hz, 1 
H, C4-H), 5.34 (td, J = 6.0, 2.4 Hz, 1 H, C7-H), 4.76 – 4.62 (comp, 2 H, C10-H), 3.76 
(dtd, J = 13.2, 5.4, 2.5 Hz, 1 H, C12-Heq), 3.70 – 3.57 (m, 1 H, C12-Hax), 2.64 (dd, J = 
14.2, 6.3 Hz, 1H, C8-Heq), 2.48 – 2.29 (comp, 6 H, C8-Hax and C11-Heq and C11-Hax and 
C17-H3). 13C NMR (101 MHz, CDCl3) δ 143.2 (C2), 140.9 (C1), 139.8 (C13), 136.3 
(C16), 132.9 (C4), 129.4 (C3), 128.6 (C6), 128.5 (C5), 127.3 (C14), 127.1 (C15), 122.3 
(C10), 112.1 (C9), 57.9 (C7), 43.8 (C12), 38.3 (C8), 31.9 (C11), 21.5 (C17). 
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2-(2,3-Dimethoxyphenyl)-4-methylene-1-tosylpiperidine (2.80b). Prepared in 
accord with the representative procedure to yield 20 mg (60%) of the title compound as a 
white solid. 1H NMR (400 MHz,CDCl3) δ 7.67 – 7.61 (comp, 2 H), 7.24 – 7.17 (comp, 2 
H), 6.93 – 6.84 (comp, 2 H), 6.79 (dd, J = 7.7, 2.0 Hz, 1 H), 5.54 (dd, J = 6.7, 4.2 Hz, 1 
H), 4.75 – 4.61 (comp, 2 H), 3.90 (s, 3 H), 3.87 – 3.77 (comp, 4 H), 3.51 – 3.40 (m, 1 H), 
2.60 (dd, J = 14.0, 6.7 Hz, 1 H), 2.51 (dd, J = 14.0, 4.2 Hz, 1 H), 2.39 (s, 3 H), 2.33 – 
2.24 (comp, 2 H). 13C NMR (151 MHz, CDCl3) δ 152.6, 146.0, 142.9, 140.9, 137.4, 
135.5, 129.3, 127.2, 123.2, 119.8, 111.5, 111.4, 60.6, 55.7, 53.4, 52.6, 43.0, 38.7, 32.2, 
21.5. HRMS (ESI) m/z calcd for C21H25NO4S (M+Na)+, 410.1397; found, 410.1409 
NMR Assignments. For 2.80b: 1H NMR (400 MHz,CDCl3) δ 7.67 – 7.61 (comp, 
2 H, C16-H), 7.24 – 7.17 (comp, 2 H, C17-H), 6.93 – 6.84 (comp, 2 H, C4-H and C5-H), 
6.79 (dd, J = 7.7, 2.0 Hz, 1 H, C6-H), 5.54 (dd, J = 6.7, 4.2 Hz, 1 H, C9-H), 4.75 – 4.61 
(comp, 2 H, C12-H2), 3.90 (s, 3 H, C7-H or C8-H), 3.87 – 3.77 (comp, 4 H, C7-H or C8-
H; and C14-Heq), 3.51 – 3.40 (m, 1 H, C14-Hax), 2.60 (dd, J = 14.0, 6.7 Hz, 1 H, C10-
Heq), 2.51 (dd, J = 14.0, 4.2 Hz, 1 H, C10-Hax), 2.39 (s, 3 H, C19-H3), 2.33 – 2.24 (comp, 
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2 H, C13-Heq and C13-Hax). 13C NMR (151 MHz, CDCl3) δ 152.6 (C2), 146.0 (C3), 142.9 
(C1), 140.9 (C6), 137.4 (C4), 135.5 (C5), 129.3 (C15), 127.2 (C18), 123.2 (C16), 119.8 
(C17), 111.5 (C12), 111.4 (C11), 55.7 (C9), 53.4 (C7 or C8), 52.6 (C7 or C8), 43.0 
(C14), 38.7 (C10), 32.2 (C13), 21.5 (C19). 
 
 
2-(3,4-Dimethoxyphenyl)-4-methylene-1-tosylpiperidine (2.80c). Prepared in 
accord with the representative procedure to yield 20 mg (60%) of the title compound as a 
white solid. 1H NMR (400 MHz, CDCl3) δ 7.76 – 7.72 (comp, 2 H), 7.30 – 7.21 (comp, 2 
H), 6.92 (ddd, J = 8.3, 2.2, 0.9 Hz, 1 H), 6.86 (d, J = 2.1 Hz, 1 H), 6.75 (d, J = 8.3 Hz, 1 
H), 5.26 (d, J = 6.3 Hz, 1 H), 4.86 – 4.80 (comp, 2 H), 3.84 (comp, 4 H), 3.74 (s, 3 H), 
2.94 (ddd, J = 13.9, 12.0, 4.1 Hz, 1 H), 2.76 (d, J = 14.2 Hz, 1 H), 2.49 (ddd, J = 14.2, 
6.3, 1.5 Hz, 1 H), 2.41 (s, 3 H), 2.23 – 2.06 (comp, 2 H). 13C NMR (151 MHz, CDCl3) δ 
148.7, 148.1, 143.1, 141.5, 138.5, 131.7, 129.7, 127.0, 120.1, 112.0, 111.2, 110.6, 55.8, 
55.7, 55.3, 41.7, 36.1, 33.2, 21.5. HRMS (ESI) m/z calcd for C21H25NO4S (M+Na)+, 
410.1397; found, 410.1403 
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 NMR Assignments. For 2.80c: 1H NMR (400 MHz, CDCl3) δ 7.76 – 7.72 (comp, 
2 H, C16-H), 7.30 – 7.21 (comp, 2 H, C17-H), 6.92 (ddd, J = 8.3, 2.2, 0.9 Hz, 1 H, C6-
H), 6.86 (d, J = 2.1 Hz, 1 H, C5-H), 6.75 (d, J = 8.3 Hz, 1 H, C2-H), 5.26 (d, J = 6.3 Hz, 
1 H, C9-H), 4.86 – 4.80 (comp, 2 H, C12-H2), 3.84 (comp, 4 H, C7-H3 or C8-H3; and 
C14-Heq), 3.74 (s, 3 H, C7-H3 or C8-H3), 2.94 (ddd, J = 13.9, 12.0, 4.1 Hz, 1 H, C14-Hax), 
2.76 (d, J = 14.2 Hz, 1 H, C10-Heq), 2.49 (ddd, J = 14.2, 6.3, 1.5 Hz, 1 H, C10-Hax), 2.41 
(s, 3 H, C19-H3), 2.23 – 2.06 (comp, 2 H, C13-Heq and C13-Hax). 13C NMR (151 MHz, 
CDCl3) δ 148.7 (C2 or C5), 148.1 (C2 or C5), 143.1 (C1), 141.5 (C3 or C4), 138.5 (C3 or 
C4), 131.7 (C6), 129.7 (C15), 127.0 (C18), 120.1 (C16), 112.0 (C17), 111.2 (C12), 110.6 
(C11), 55.8 (C7 or C8 or C9), 55.7 (C7 or C8 or C9), 55.3 (C7 or C8 or C9), 41.7 (C14), 
36.1 (C10), 33.2 (C13), 21.5 (C19). 
 
 
 
2-(2,5-Dimethoxyphenyl)-4-methylene-1-tosylpiperidine (2.80d). Prepared in 
accord with the representative procedure to yield 20 mg (60%) of the title compound as a 
clear oil. 1H NMR (400 MHz,CDCl3) δ 7.61 – 7.56 (comp, 2 H), 7.22 – 7.15 (comp, 2 H), 
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6.95 – 6.91 (m, 1 H), 6.71 – 6.68 (comp, 2 H), 5.55 (dd, J = 6.4, 3.9 Hz, 1 H), 4.82 – 4.65 
(comp, 2 H), 3.88 – 3.79 (m, 1 H), 3.68 (s, 3 H), 3.66 (s, 3 H), 3.38 (ddd, J = 13.5, 10.9, 
4.5 Hz, 1 H), 2.70 – 2.55 (comp, 2 H), 2.45 – 2.25 (comp, 5 H). 13C NMR (151 MHz, 
CDCl3) δ 152.9, 150.6, 142.6, 141.7, 137.9, 130.2, 129.2, 127.0, 114.9, 112.3, 111.4, 
111.2, 55.6, 55.5, 51.9, 42.9, 37.9, 33.0, 21.4. HRMS (ESI) m/z calcd for C21H25NO4S 
(M+Na)+, 410.1397; found, 410.1410 
 NMR assignments: For 2.80d: 1H NMR (400 MHz,CDCl3) δ 7.61 – 7.56 (comp, 
2 H, C14-H), 7.22 – 7.15 (comp, 2 H, C15-H), 6.95 – 6.91 (m, 1 H, C6-H), 6.71 – 6.68 
(comp, 2 H, C3-H and C4-H), 5.55 (dd, J = 6.4, 3.9 Hz, 1 H, C9-H), 4.82 – 4.65 (comp, 2 
H, C12-H2), 3.88 – 3.79 (m, 1 H, C14-Heq), 3.68 (s, 3 H, C7-H or C8-H), 3.66 (s, 3 H, 
C7-H or C8-H), 3.38 (ddd, J = 13.5, 10.9, 4.5 Hz, 1 H, C14-Hax), 2.70 – 2.55 (comp, 2 H, 
C10-He q and C10-Hax), 2.45 – 2.25 (comp, 5 H, C13-Heq and C13-Hax and C19-H3). 13C 
NMR (151 MHz, CDCl3) δ 152.9 (C2), 150.6 (C5), 142.6 (C1), 141.7 (C4 or C3), 137.9 
(C4 or C3), 130.2 (C6), 129.2 (C15), 127.0 (C18), 114.9 (C16), 112.3 (C17), 111.4 
(C12), 111.2 (C11), 55.6 (C7 or C8), 55.5 (C7 or C8), 51.9 (C9), 42.9 (C14), 37.9 (C10), 
33.0 (C13), 21.4 (C19). 
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2-(4-Bromo-2-fluorophenyl)-4-methylene-1-tosylpiperidine (2.80e). Prepared 
in accord with the representative procedure to yield 20 mg (65%) of the title compound 
as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.66 – 7.60 (comp, 2 H), 7.30 – 7.20 
(comp, 3 H), 7.18 – 7.10 (comp, 2 H), 5.41 (t, J = 5.0 Hz, 1 H), 4.80 – 4.69 (comp, 2 H), 
3.81 (dt, J = 13.5, 4.5 Hz, 1 H), 3.28 (ddd, J = 13.6, 9.7, 5.6 Hz, 1 H), 2.59 (d, J = 5.0 Hz, 
2 H), 2.41 (s, 3 H), 2.32 – 2.22 (m, 2 H). 13C NMR (151 MHz, CDCl3) δ 159.7 (d, J = 
252.0 Hz), 143.3, 140.4, 137.1, 130.1 (d, J = 4.5 Hz), 129.5, 127.0 (d, J = 17.6 Hz), 126.9 
(d, J = 9.3 Hz), 121.4 (d, J = 9.8 Hz), 119.2 (d, J = 25.9 Hz), 112.1, 51.6, 42.9, 37.7, 
32.6, 21.5. HRMS (ESI) m/z calcd for C19H19BrFNO2S (M+Na)+, 446.0196; found, 
446.0201 
 NMR assignments. For 2.80e: 1H NMR (400 MHz, CDCl3) δ 7.66 – 7.60 (comp, 
2 H, C5-H and C6-H), 7.30 – 7.20 (comp, 3 H, C14-H and C3-H), 7.18 – 7.10 (comp, 2 
H, C15), 5.41 (t, J = 5.0 Hz, 1 H, C9-H), 4.80 – 4.69 (comp, 2 H, C10-H2), 3.81 (dt, J = 
13.5, 4.5 Hz, 1 H, C12-Heq), 3.28 (ddd, J = 13.6, 9.7, 5.6 Hz, 1 H, C12-Hax), 2.59 (d, J = 
5.0 Hz, 2 H, C8-Heq and C8-Hax), 2.41 (s, 3 H, C17-H3), 2.32 – 2.22 (comp, 2 H, C11-Heq 
and C11-Hax). 13C NMR (151 MHz, CDCl3) δ 159.7 (d, J = 252.0 Hz, C2), 143.3 (C13), 
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140.4 (C16), 137.1 (C14), 130.1 (d, J = 4.5 Hz, C5), 129.5 (C15), 127.0 (d, J = 17.6 Hz, 
C1), 126.9 (d, J = 9.3 Hz, C4), 121.4 (d, J = 9.8 Hz, C6), 119.2 (d, J = 25.9 Hz, C3), 
112.1 (C10), 51.6 (C7), 42.9 (C12), 37.7 (C8), 32.6 (C11), 21.5 (C17). 
 
 
 2-(3,5-Dichlorophenyl)-4-methylene-1-tosylpiperidine (145). Prepared in 
accord with the representative procedure to yield 25 mg (76%) of the title compound as a 
white solid. 1H NMR (400 MHz, CDCl3) δ 7.75 – 7.69 (m, 2 H), 7.32 – 7.27 (m, 2 H), 
7.22 – 7.19 (m, 1 H), 7.19 – 7.15 (m, 2 H), 5.22 (d, J = 6.3 Hz, 1 H), 4.85 – 4.77 (m, 2 
H), 3.96 – 3.87 (m, 1 H), 3.03 – 2.86 (m, 1 H), 2.66 (dd, J = 14.5, 2.2 Hz, 1 H), 2.43 (s, 4 
H), 2.14 – 2.07 (m, 2 H). 13C NMR (101 MHz, CDCl3) δ 143.6, 142.7, 139.9, 137.9, 
135.0, 129.9, 127.4, 127.0, 126.2, 112.8, 55.2, 42.1, 36.0, 32.8, 21.5. HRMS (ESI) m/z 
calcd for C19H19Cl2NO2S (M+Na)+, 418.0406; found, 418.0414 
 NMR assignments. For 2.80f: 1H NMR (400 MHz, CDCl3) δ 7.75 – 7.69 (comp, 
2 H, C14-H), 7.32 – 7.27 (comp, 2 H, C15-H), 7.22 – 7.19 (m, 1 H, C4-H), 7.19 – 7.15 
(m, 2 H, C6 and C2-H), 5.22 (d, J = 6.3 Hz, 1 H, C7-H), 4.85 – 4.77 (m, 2 H, 10-H2), 
3.96 – 3.87 (m, 1 H, C12-Heq), 3.03 – 2.86 (m, 1 H, C12-Hax), 2.66 (dd, J = 14.5, 2.2 Hz, 
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1 H, C8-Heq), 2.43 (s, 4 H, C8-Hax and C17-H3), 2.14 – 2.07 (m, 2 H, C11-Heq and C11-
Hax). 13C NMR (101 MHz, CDCl3) δ 143.6 (C3 and C5), 142.7 (C1), 139.9 (C6 and C2), 
137.9 (C4), 135.0 (C13), 129.9 (C16), 127.4 (C14), 127.0 (C15), 126.2 (C10), 112.8 
(C9), 55.2 (C7), 42.1 (C12), 36.0 (C8), 32.8 (C11), 21.5 (C17). 
 
 
 
 2-(Benzo[d][1,3]dioxol-5-yl)-4-methylene-1-tosylpiperidine (2.80g). Prepared 
in accord with the representative procedure to yield 11 mg (32%) of the title compound 
as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.77 – 7.69 (comp, 2 H), 7.26 (comp, 2 
H), 6.88 (d, J = 1.9 Hz, 1 H), 6.86 – 6.82 (m, 1 H), 6.70 (d, J = 8.0 Hz, 1 H), 5.92 (d, J = 
0.8 Hz, 2 H), 5.22 (d, J = 6.5 Hz, 1 H), 4.80 (comp, 2 H), 3.88 – 3.80 (m, 1 H), 2.98 (ddd, 
J = 14.0, 10.4, 5.7 Hz, 1 H), 2.71 – 2.64 (m, 1 H), 2.42 (comp, 4 H), 2.14 – 2.07 (comp, 2 
H). 13C NMR (101 MHz, CDCl3) δ 147.7, 146.6, 143.2, 141.0, 138.3, 133.2, 129.7, 127.0, 
121.2, 112.2, 108.4, 107.8, 101.0, 55.5, 41.7, 36.2, 32.9, 21.5. HRMS (ESI) m/z calcd for 
C20H21NO4S (M+Na)+, 394.1083; found, 394.1089 
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 NMR assignments. For 2.80g: 1H NMR (400 MHz, CDCl3) δ 7.77 – 7.69 (comp, 
2 H (C15-H), 7.26 (comp, 2 H, C15-H), 6.88 (d, J = 1.9 Hz, 1 H, C6-H), 6.86 – 6.82 (m, 
1 H, C2-H), 6.70 (d, J = 8.0 Hz, 1 H, C3-H), 5.92 (d, J = 0.8 Hz, 2 H, C7-H2), 5.22 (d, J = 
6.5 Hz, 1 H, C8-H), 4.80 (comp, 2 H, C11-H2), 3.88 – 3.80 (m, 1 H (C13-Heq), 2.98 (ddd, 
J = 14.0, 10.4, 5.7 Hz, 1 H, C13-Hax), 2.71 – 2.64 (m, 1 H, C9-Heq), 2.42 (comp, 4 H, C9-
Hax and C18-H3), 2.14 – 2.07 (comp, 2 H, C12-Heq and C12-Hax). 13C NMR (101 MHz, 
CDCl3) δ 147.7 (C5 or C4), 146.6 (C5 or C4), 143.2 (C1), 141.0 (C14), 138.3 (C17), 
133.2 (C15), 129.7 (C16), 127.0 (C6), 121.2 (C2), 112.2 (C3), 108.4 (C11), 107.8 (C12), 
101.0 (C7), 55.5 (C8), 41.7 (C13), 36.2 (C9), 32.9 (C12), 21.5 (C18). 
 
 
 
4-Methylene-2-(thiophen-3-yl)-1-tosylpiperidine (2.80h). Prepared in accord 
with the representative procedure to yield 31 mg (83%) of the title compound as a clear 
oil. 1H NMR (400 MHz, CDCl3) δ 7.73 – 7.68 (comp, 2 H), 7.30 – 7.23 (comp, 2 H), 7.19 
(dd, J = 5.0, 3.0 Hz, 1H), 7.15 (dt, J = 2.9, 1.3 Hz, 1H), 6.97 (dd, J = 5.0, 1.4 Hz, 1H), 
5.38 – 5.30 (m, 1 H), 4.87 – 4.76 (comp, 2 H), 3.90 – 3.79 (m, 1 H), 2.93 (ddd, J = 13.8, 
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11.1, 5.0 Hz, 1H), 2.69 – 2.60 (m, 1 H), 2.55 – 2.45 (m, 1 H), 2.41 (s, 3 H), 2.21 – 2.05 
(comp, 2 H). 13C NMR (101 MHz, CDCl3) δ 143.1, 141.3, 140.4, 138.2, 129.7, 127.8, 
127.0, 125.4, 123.0, 112.2, 52.8, 41.8, 37.1, 33.3, 21.5. HRMS (ESI) m/z calcd for 
C17H19NO2S2 (M+Na)+, 356.0749; found, 356.0755. 
NMR assignments. For 2.80h: 1H NMR (400 MHz, CDCl3) δ 7.73 – 7.68 (comp, 
2 H, C12-H), 7.30 – 7.23 (comp, 2 H, C13-H), 7.19 (dd, J = 5.0, 3.0 Hz, 1H, C4-H), 7.15 
(dt, J = 2.9, 1.3 Hz, 1H, C3-H), 6.97 (dd, J = 5.0, 1.4 Hz, 1H, C1-H), 5.38 – 5.30 (m, 1H, 
C5-H), 4.87 – 4.76 (comp, 2 H, C8-H2), 3.90 – 3.79 (m, 1H, C10-Heq), 2.93 (ddd, J = 
13.8, 11.1, 5.0 Hz, 1H, C10-Hax), 2.69 – 2.60 (m, 1H, C6-Heq), 2.55 – 2.45 (m, 1H, C6-
Hax), 2.41 (s, 3 H, C15-H3), 2.21 – 2.05 (comp, 2 H, C9-Heq and C9-Hax). 13C NMR (101 
MHz, CDCl3) δ 143.1 (C11), 141.3 (C14), 140.4 (C2), 138.2 (C12), 129.7 (C13), 127.8 
(C3), 127.0 (C1), 125.4 (C4), 123.0 (C8), 112.2 (C7), 52.8 (C5), 41.8 (C10), 37.1 (C6), 
33.3 (C9), 21.5 (C15). 
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